



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/15, C07K 14/81, C12N 1/21, 5/10, A61K 48/00, 38/57, 38/43, 38/17, 38/48, C07K 16/38		(11) International Publication Number: WO 95/09918 (43) International Publication Date: 13 April 1995 (13.04.95)
(21) International Application Number: PCT/US94/11241 (22) International Filing Date: 4 October 1994 (04.10.94) (30) Priority Data: 08/134,231 6 October 1993 (06.10.93) US (71) Applicant: AMGEN INC. [US/US]; Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US). (72) Inventors: SILBIGER, Scott, M.; 21520 Burbank Boulevard #114, Woodland Hills, CA 91367 (US). KOSKI, Raymond, A.; 7 Meeting House Lane, Old Lyme Road, CT 06371 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen Inc., 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).	(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LT, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: TISSUE INHIBITOR METALLOPROTEINASE TYPE THREE (TIMP-3) (57) Abstract <p>According to the present invention, a class of novel tissue inhibitors of metalloproteinase are provided. For convenience, the present polypeptides are referred to as "TIMP-3", as these polypeptides represent a new class of members of the tissue inhibitors of metalloproteinases. Also provided are DNA sequences coding for all or part of the present TIMP-3's, vectors containing such DNA sequences, and host cells transformed or transfected with such vectors. Also comprehended by the invention are methods of producing recombinant TIMP-3's, and methods of treating disorders. Additionally, pharmaceutical compositions including TIMP-3's and antibodies selectively binding TIMP-3's are provided.</p>		

PCT/US94/08661

Best Available Copy

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TISSUE INHIBITOR METALLOPROTEINASE TYPE THREE (TIMP-3).

Field of the Invention

5

The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such factors. In particular, the invention relates to novel mammalian tissue inhibitors of metalloproteinase (herein designated as type three, or "TIMP-3"), to fragments, derivatives, and analogs thereof and to polynucleotides encoding the same. In another aspect, the present invention relates to novel methods of producing such compositions, and methods of using such compositions.

15

Background of the Invention

Connective tissues are maintained in dynamic equilibrium by the opposing effects of extracellular matrix synthesis and degradation. The extracellular connective tissue matrix consists predominantly of collagens, with proteoglycans, fibronectin, laminin and other minor components making up the remainder.

25 Degradation of the matrix is brought about by the release of neutral metalloproteinases from resident connective tissue cells and invading inflammatory cells that are capable of degrading at physiological pH most of the matrix macromolecules. See Table 1, below. The proteinases include the mammalian tissue collagenases, gelatinases, and proteoglycanases; leukocyte collagenase and gelatinase (Murphy et al. Biochem. J. 283: 289-221 (1982); Hibbs et al., J. Biol. Chem. 260: 2493-2500 (1985)); macrophage collagenase and elastase (Werb et al. J. Exp. Med. 142: 346-360 (1975); Banda et al.,

30
35

- 2 -

- Biochem. J. 193: 589-605 (1981)); and tumour collagenases (Liotta et al., PNAS-USA 76: 2268-2272 (1979); Liotta et al., Biochem. Biophys. Res. Commun. 98: 124-198 (1981); and Salo et al., J. Biol. Chem. 258: 3058-3063 (1983)). For a general review of collagenases and their role in normal and pathological connective tissue turnover see Collagenase in Normal and Pathological Connective Tissues, David E. Woolley and John M. Evanson, eds., John Wiley & Sons Ltd. (1988).
- 10 There are over five different collagen types (I, II, III, IV, V, etc.) which are differentially distributed among tissues. There is considerable homology and structural similarity among the various collagen types. Particular collagenases show some
- 15 specificity for particular collagen types. See Table 1, below; Matrisian, Trends In Genetics 6: 121-125 (1990). With regard to inhibition of collagenases and other matrix-degrading metalloproteinases, it is possible
- 20 that, depending on the actual enzymes, substrates, and inhibitory mechanisms, an inhibitor could act on just one, on several, or on all collagenases and metalloproteinases.

TABLE 1
MATRIX-degrading metalloproteinases

Name(s)	Size (kDa)	Degrades	Ref.
(1) Interstitial collagenase (Type I collagenase) (MMP-1) PMN Collagenase (MMP-8)	52 decthood 52, 57 secreted 75 secreted	I, II, III collagen I, II, III collagen	Scholtz et al., Cancer Res. 48:5539-5545 (1988) Macartney et al., Eyr. J. Biochem. 130: 71-78 (1983).
(2) 72 kDa Type IV collagenase (72 kDa gelatinase) (MMP-2) 92 kDa Type IV collagenase (92 kDa gelatinase) (MMP-9)	72 secreted 78 decthood 92 secreted	IV, V, VII collagen, fibronectin, gelatins IV, V collagen, gelatins	Collier et al., J. Biol. Chem. 263:6579-6587 (1988) Withelm et al., J. Biol. Chem. 263: 17213-17221 (1989)
(3) Stromelysin (transin) (proteoglycanase) (procollagen-activating factor) (MMP 3) Stromelysin-2 (transin-2) (MMP-10) PUMP-1 (MMP-7) (Small metalloproteinase of uterus)	53 decthood 57,60 secreted 53 decthood 28 decthood 28 secreted	Proteoglycans, laminin, fibronectin, III, IV, V collagen, gelatins III, IV, V collagen, fibronectin, gelatins Gelatins, fibronectin	Chin et al., J. Biol. Chem. 260: 12367-12376 (1985) Nicholson et al., Biochemistry 28: 5195-5203 (1989) Quantin et al., Biochemistry 28: 5327-5333 (1989)

The matrix metalloproteinases are divided into three major subclasses, indicated with arabic numerals, on the basis of their substrate specificities. The enzymes in each class are bold, and alternative names are shown in parentheses. MMP, matrix metalloproteinase; PMN, polymorphonuclear leukocyte.

- 4 -

The underlying basis of degradative diseases of connective tissue points to the matrix-specific metalloproteinases as having a fundamental role in the etiology of these diseases. Such diseases include
5 dystrophic epidermolysis bullosa; rheumatoid arthritis; corneal, epidermal or gastric ulceration; periodontal disease; emphysema; bone disease; and tumor metastasis or invasion.

Most studies on connective tissue degradation
10 and diseases involving such degradation have limited the measurement of metalloproteinases to collagenase (the most widely studied of this group of metalloproteinases). It is understood however, that the simultaneous effects of collagenase and the other
15 matrix-degrading metalloproteinases will exacerbate the degradation of the connective tissue over that achieved by collagenase alone.

Specific natural inhibitors of collagenase were discovered in crude medium from cultured connective
20 tissues. A metalloproteinase inhibitor known as TIMP (tissue inhibitor of metalloproteinases) has been studied with regard to physicochemical properties and the biochemistry of its interaction with collagenase, Murphy et al., J. Biochem. 195: 167-170 (1981); Cawston
25 et al., J. Biochem. 211: 313-318 (1983); Stricklin et al., J. Biol. Chem. 258: 12252-12258 (1983), and DNA encoding it has been isolated, Docherty et al., Nature 318: 65-69 (1985); Carmichael et al., PNAS-USA 83: 2407-2411 (1986). In an in vitro cell culture model of tumor
30 cell migration through a natural basement membrane, TIMP was able to arrest migration of a collagenase-secreting tumor cell line, Thorgeirsson et al., J. Natl. Canc. Inst. 69: 1049-1054 (1982). In vivo mouse lung colonization by murine B16-F10 melanoma cells was
35 inhibited by injections of TIMP, Schultz et al., Cancer

- 5 -

Research 48: 5539-5545 (1988). European Patent
Publication No. EP O 189 784 also relates to TIMP.

McCartney et al., Eur. J. Biochem. 130: 79-83
(1983) reported the purification of a metalloproteinase
5 inhibitor from human leukocytes.

DeClerck et al., Cancer Research 46: 3580-3586
(1986) described the presence of two inhibitors of
collagenase in conditioned medium from bovine aortic
endothelial cells.

10 Murray et al., J. Biol. Chem. 261: 4154-4159
(1986) reported the purification and partial amino acid
sequence of a bovine cartilage-derived collagenase
inhibitor.

Langley, et al., EP O 398 753
15 ("Metalloproteinase Inhibitor," published November 22,
1990) discloses a novel metalloproteinase inhibitor and
analog, polynucleotides encoding the same, methods of
production, pharmaceutical compositions, and methods of
treatment. The polypeptide of Figure 2 therein has been
20 referred to as TIMP-2, designating a molecule distinct
from TIMP-1, supra. EP O 398 753 describes both bovine
and human recombinant TIMP-2.

Staskus et al., J. Biol. Chem. 266: 449-454
(1991) reports a 21 kDa avian metalloproteinase
25 inhibitor obtained from chicken fibroblasts. The
authors note the biochemical similarities with other
members of the TIMP and TIMP-2 group of proteins and
state that the avian material may be a TIMP variant or
may represent a third protein within the
30 metalloproteinase inhibitor family. (This material is
referred to herein as "ChIMP-3")

Pavloff et al., J. Biol. Chem. 267: 17321-
17326 (1992) discloses the cDNA and primary structure of
a metalloproteinase inhibitor from chicken embryo
35 fibroblasts.

- 6 -

Yang et al., PNAS-USA 89: 10676-10680 (1992)
reports on the role of a 21 kDa protein chicken TIMP-3.

The present work relates to a third type of
metalloproteinase inhibitor polypeptides. In one
5 aspect, the present invention involves the cloning of
recombinant human TIMP-3 nucleic acid and expression
thereof.

Summary of the Invention

10

According to the present invention, a class of
novel tissue inhibitors of metalloproteinase are
provided. For convenience, the present polypeptides are
referred to as "TIMP-3," as these polypeptides represent
15 a new class of members of the tissue inhibitors of
metalloproteinases. Also provided are DNA sequences
coding for all or part of the present TIMP-3's, vectors
containing such DNA sequences, and host cells
transformed or transfected with such vectors. Also
20 comprehended by the invention are methods of producing
recombinant TIMP-3's, and methods of treating disorders.
Additionally, pharmaceutical compositions including
TIMP-3's and antibodies selectively binding TIMP-3's are
provided.

25

Brief Description of the Drawings

Figure 1 shows the cDNA sequence and amino
acid sequence of a recombinant human tissue inhibitor of
30 metalloproteinase type 3 ("TIMP-3"). The entire 1240
base pair sequence encoding a full-length polypeptide of
211 amino acids is presented. A hydrophobic leader
sequence is found at position -23 to -1. The initial
cysteine of the mature protein is numbered +1. The
35 amino acids corresponding to the degenerate

- 7 -

oligonucleotides which identified the original PCR products are underlined, except that the oligo corresponding to YTIK was used analytically to confirm the identity of the PCR products prior to sequencing. A potential glycosylation site is italicized. A variant polyadenylation signal sequence is marked with asterisks. (The abbreviations used herein for amino acids, either single letter or triple letter abbreviations, and nucleic acids are those conventionally used, as in Stryer, Biochemistry, 3d ed. 1988, W.H. Freeman, N.Y., inside back cover.)

Figure 2 is a photograph of an agarose gel of first-strand cDNA PCR products, which demonstrate amplification of human nucleic acid. Lane of 1 presents PCR products from human fetal kidney first strand cDNA primed with primers 449-15 (Seq. ID No. 1) and 480-27 (Seq. ID No. 2). Lane 2 presents the results of PCR amplification of fetal kidney first strand cDNA primed with primers 449-15 (Seq. ID No. 12) and 480-28 (Seq. ID No. 3). Lane 3 is the PCR kit (Perkin-Elmer-Cetus) control. Lane 4 is TIMP-2 DNA primed with primers 449-15 (Seq. ID No. 1) and 480-27 (Seq. ID No. 2). Lane 5 is molecular weight markers.

25

Figure 3 is a photograph of a silver stained SDS-PAGE gel containing material as follows: Lane 1, molecular weight markers; lane 2, TIMP-2, reduced; lane 3, blank; lane 4, E. coli derived TIMP-3 of Figure 1, reduced, post-dialysis; lane 5, E. coli derived TIMP-3 of Figure 1, reduced, post-dialysis, lanes 6, 7, 8, blank; lane 9, E. coli derived TIMP-3 of Figure 1, unreduced, pre-dialysis; lane 10, E. coli derived TIMP-3 of Figure 1, unreduced, post-dialysis.

35

- 8 -

Figure 4 is a comparison table of human TIMP-3 amino acid sequence of Figure 1 with other TIMP family members. The numbering begins with the first cysteine of the mature protein. As can be seen, the alignment contains gaps for some TIMP family members. The numbering used here is consistent for the numbering used for the recombinant human TIMP-3 of Figure 1. Boldface letters indicate conserved amino acids; asterisks represent potential glycosylation sites of TIMP-1; underlined letters indicate potential glycosylation sites of TIMP-3; the left bracket indicates the beginning of the mature proteins. A bullet (•) indicates those amino acids which are unique to recombinant human TIMP-3. The amino acid sequences were found in the literature as follows: Bovine TIMP-1, Freudenstein et al., Biochem. Physic. Res. Comm. 171: 250-256 (1990); Human TIMP-1, Docherty et al., Nature 318: 65-69 (1985); Rabbit TIMP-1, Horowitz et al., J. Biol. Chem. 264: 7092-7095 (1989); Mouse TIMP-1, Edwards et al., Nucleic Acid. Res. 14: 8863-8878 (1986); Johnson et al., Mol. Cell. Biol. 7: 2821-2829 (1978); Gewert et al., EMBO 6: 651-657 (1987); Bovine TIMP-2, Boone et al., PNAS-USA 87: 2800-2804 (1990); Human TIMP-2, Boone et al., PNAS-USA 87: 2800-2804 (1990); Mouse TIMP-2, Shimizu et al., Gene 114: 291-292 (1992); Chicken TIMP-3, Pavloff et al., J. Biol. Chem. 267: 17321-17326 (1992). Unless otherwise indicated, these sequences referred to from time to time herein were found in these references.

30

Figure 5 is a comparison table of the amino acid sequence for the chicken metalloproteinase inhibitor of Staskus et al., J. Biol. Chem. 266: 449-454 (1991) and the recombinant human TIMP-3 of Figure 1. A solid line between amino acids indicates identity,

35

- 9 -

double dots indicates similarity. A single dot indicates a lesser degree of similarity, and no dot indicates total difference, as described by Grivskov et al., Nucl. Acid. Res. 14: 6745-6763 (1986).

5

Figure 6 shows the overall homology between the Figure 1 nucleic acid sequence encoding TIMP-3 and that encoding ChIMP-3.

10

Figure 7 shows the maximal homology between the Figure 1 nucleic acid sequence encoding TIMP-3 and that encoding ChIMP-3.

15

Figure 8 shows the amino acid sequence alignment of human recombinant TIMP-3 of Figure 1 and human TIMP-2.

20

Figure 9 shows the overall homology of the Figure 1 nucleic acid sequence of human recombinant TIMP-3 and that encoding human TIMP-2.

25

Figure 10 shows the maximal homology regions of the Figure 1 nucleic acid sequence encoding human recombinant TIMP-3 and that encoding human TIMP-2.

30

Figure 11 shows the amino acid sequence alignment of human recombinant TIMP-3 of Figure 1 and human TIMP-1.

Figure 12 shows the overall homology of the Figure 1 nucleic acid sequence encoding human recombinant TIMP-3 and that encoding human TIMP-1.

- 10 -

Figure 13 shows the maximal homology regions of the Figure 1 nucleic acid sequence encoding human recombinant TIMP-3 and that encoding human TIMP-1.

5 Figures 14 A and B shows Northern blot analyses performed on RNAs from a variety of cells, using a TIMP-3 DNA fragment as a probe.

10 Figure 15 shows a modified zymogram. Lane 1 (from the left hand side) contains a protein molecular weight standard (see Figure 3). Lane 2 is a control lane containing conditioned medium with collagenases (72 kDa and interstitial collagenases, pAPMA activated). ("Coll" refers to interstitial collagenase.) Lane 3
15 contains TIMP-2. Lane 4 contains a TIMP-2 analog lacking the six C-terminal cysteines. Lanes 5, 6, and 7 contain E. coli derived TIMP-3 of Figure 1, lane 5 being undiluted and lanes 6 and 7 being consecutive 2-fold
20 serial dilutions. As can be seen, the lack of a clear zone at the location where the control (lane 2) showed clearing indicates that TIMP-3 inhibits collagenase activity.

25 Figure 16 shows the cDNA and amino acid sequence of variants obtained using the present method.

30 Figure 17 shows an illustration of a proposed secondary structure of members of the TIMP family of proteins.

35 Numerous aspects and advantages of the invention will be apparent to those skilled in the art upon consideration of the following detailed description which provides illustrations of the practice of the invention in its presently preferred embodiments.

- 11 -

Detailed Description of the Invention

5 According to the present invention, novel
metalloproteinase inhibitors (herein called,
collectively, TIMP-3) and DNA sequences coding for all
or part of such TIMP-3 are provided. Such sequences
include the incorporation of codons "preferred" for
10 expression by selected nonmammalian hosts; the provision
of sites for cleavage by restriction endonuclease
enzymes; and the provision of additional initial,
terminal or intermediate DNA sequences which facilitate
construction of readily expressed vectors. The present
15 invention also provides DNA sequences coding for
polypeptide analogs or derivatives of TIMP-3 which
differ from naturally-occurring forms in terms of the
identity or location of one or more amino acid residues
(i.e., deletion analogs containing less than all of the
20 residues specified for TIMP-3; substitution analogs,
wherein one or more residues specified are replaced by
other residues; and addition analogs wherein one or more
amino acid residues is added to a terminal or medial
portion of the polypeptide) and which share some or all
25 the biological properties of mammalian TIMP-3.

Novel nucleic acid sequences of the invention
include sequences useful in securing expression in
procaryotic or eucaryotic host cells of polypeptide
products having at least a part of the primary
30 structural conformation and one or more of the
biological properties of recombinant human TIMP-3. The
nucleic acids may be purified and isolated, so that the
desired coding region is useful to produce the present
polypeptides, for example, or for diagnostic purposes,
35 as described more fully below. DNA sequences of the

- 12 -

invention specifically comprise: (a) the DNA sequence set forth in Figure 1 (and complementary strands); (b) a DNA sequence which hybridizes (under hybridization conditions disclosed in the cDNA library screening section below, or equivalent conditions or more stringent conditions) to the DNA sequence in Figure 1 or to fragments thereof; and (c) a DNA sequence which, but for the degeneracy of the genetic code, would hybridize to the DNA sequence in Figure 1. Also contemplated are fragments of (a), (b) or (c) above which are at least long enough to selectively hybridize to human genomic DNA encoding TIMP-3, under conditions disclosed for the cDNA library screening, below. Specifically comprehended in parts (b) and (c) are genomic DNA sequences encoding allelic variant forms of human TIMP-3 and/or encoding TIMP-3 from other mammalian species, and manufactured DNA sequences encoding TIMP-3, fragments of TIMP-3, and analogs of TIMP-3 which DNA sequences may incorporate codons facilitating transcription and translation of messenger RNA in microbial hosts. Such manufactured sequences may readily be constructed according to the methods of Alton et al., PCT published application WO 83/04053.

Genomic DNA encoding the present TIMP-3's may contain additional non-coding bases, or introns, and such genomic DNAs are obtainable by hybridizing all or part of the cDNA, illustrated in Figures 1 and 16, to a genomic DNA source, such as a human genomic DNA library. Such genomic DNA will encode functional TIMP-3 polypeptide; however, use of the cDNAs may be more practicable in that, since only the coding region is involved, recombinant manipulation is facilitated.

According to another aspect of the present invention, the DNA sequences described herein which encode TIMP-3 polypeptides are valuable for the

- 13 -

information which they provide concerning the amino acid sequence of the mammalian protein which have heretofore been unavailable. Put another way, DNA sequences provided by the invention are useful in generating new
5 and useful viral and circular plasmid DNA vectors, new and useful transformed and transfected procaryotic and eucaryotic host cells (including bacterial and yeast cells and mammalian cells grown in culture), and new and useful methods for cultured growth of such host cells
10 capable of expression of TIMP-3 and its related products.

The DNA provided herein (or corresponding RNAs) may also be used for gene therapy for, example, treatment of emphysema. For example, transgenic mice
15 overexpressing collagenase exhibit symptoms pulmonary emphysema, D'Armiento et al., Cell 71: 955-961 (1992), indicating that inhibition of collagenase may ameliorate some of the symptoms of emphysema. Currently, vectors suitable for gene therapy (such as retroviral or
20 adenoviral vectors modified for gene therapy purposes and of purity and pharmaceutical acceptability) may be administered for delivery into the lung. Such vectors may incorporate nucleic acid encoding the present polypeptides for expression in the lung. Additionally,
25 one may use a mixture of such vectors, such as those containing genes for one or more TIMPs, elastase inhibitors or other proteins which ameliorate the symptoms of emphysema. Gene therapy may involve a vector containing more than one gene for a desired
30 protein.

Alternatively, one may use no vector so as to facilitate relatively stable presence in the host. For example, homologous recombination may facilitate
integration into a host genome. The nucleic acid may be
35 placed within a pharmaceutically acceptable carrier to

- 14 -

facilitate cellular uptake, such as a lipid solution carrier (e.g., a charged lipid), a liposome, or polypeptide carrier (e.g., polylysine). A review article on gene therapy is Verma, Scientific American, 5 November 1990, pages 68-84 which is herein incorporated by reference.

As mentioned above, target cells may be within the lungs of the recipient, but other target cells may be bone marrow cells, blood cells, liver (or other 10 organ) cells, muscle cells, fibroblasts, or other cells. The desired nucleic acid may be first placed within a cell, and the cell may be administered to a patient (such as a transplanted tissue) or the desired nucleic acid may be administered directly to the patient for 15 uptake in vivo.

The cells to be transferred to the recipient may be cultured using one or more factors affecting the growth or proliferation of such cells, as for example, SCF.

20 Administration of DNA of the present invention to the lung may be accomplished by formation of a dispersion of particles, or an aerosol. Typically some type of bulking agent will be involved, and a carrier, such as a lipid or polypeptide. These materials must be 25 pharmaceutically acceptable. One may use a nebulizer for such delivery, such an ultrasonic or dry powder nebulizer. Alternatively, one may use a propellant based system, such as a metered dose inhaler, which may deliver liquid or a suspension of particles.

30 For gene therapy dosages, one will generally use between one copy and several thousand copies of the present nucleic acid per cell, depending on the vector, the expression system, the age, weight and condition of the recipient and other factors which will be apparent 35 to those skilled in the art.

- 15 -

DNA sequences of the invention are also suitable materials for use as labeled probes in isolating human genomic DNA encoding TIMP-3, as mentioned above, and related proteins as well as cDNA and genomic DNA sequences of other mammalian species. DNA sequences may also be useful in various alternative methods of protein synthesis (e.g., in insect cells) or, as described above, in genetic therapy in humans and other mammals. DNA sequences of the invention are expected to be useful in developing transgenic mammalian species which may serve as eucaryotic "hosts" for production of TIMP-3 and TIMP-3 products in quantity. See, generally, Palmiter et al., Science 222: 809-814 (1983).

Also, one may prepare antisense nucleic acids against the present DNAs. Compare, Khokho et al., Science 243: 947-950 (1989), whereby antisense RNA inhibitor of TIMP conferred oncogenicity on Swiss 3T3 cells. Antisense nucleic acids may be used to modulate or prevent expression of endogenous TIMP-3 nucleic acids.

The present invention provides purified and isolated polypeptide products having part or all of the primary structural conformation (i.e., continuous sequence of amino acid residues) and one or more of the biological properties (e.g., immunological properties and in vitro biological activity) and physical properties (e.g., molecular weight) of naturally-occurring mammalian TIMP-3 including allelic variants thereof. The term "purified and isolated" herein means substantially free of unwanted substances so that the present polypeptides are useful for an intended purpose. For example, one may have a recombinant human TIMP-3 substantially free of other human proteins or pathological agents. These polypeptides are also

- 16 -

characterized by being the a product of mammalian cells, or the product of chemical synthetic procedures or of procaryotic or eucaryotic host expression (e.g., by bacterial, yeast, higher plant, insect and mammalian
5 cells in culture) of exogenous DNA sequences obtained by genomic or cDNA cloning or by gene synthesis. The products of expression in typical yeast (e.g., Saccharomyces cerevisiae) or procaryote (e.g., E. coli) host cells are free of association with any mammalian
10 proteins. The products of expression in vertebrate (e.g., non-human mammalian (e.g. COS or CHO) and avian) cells are free of association with any human proteins. Depending upon the host employed, and other factors, polypeptides of the invention may be glycosylated with
15 mammalian or other eucaryotic carbohydrates or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue (at position -1 with respect to the first amino acid residue of the polypeptide).

20 In addition to naturally-occurring allelic forms of TIMP-3, the present invention also embraces other TIMP-3 products such as polypeptide analogs of TIMP-3 and fragments of TIMP-3. Following the procedures of the above noted published application by
25 Alton et al. (WO 83/04053), one can readily design and manufacture genes coding for microbial expression of polypeptides having primary conformations which differ from that herein specified for in terms of the identity or location of one or more residues (e.g.,
30 substitutions, terminal and intermediate additions and deletions). Alternately, modifications of cDNA and genomic genes may be readily accomplished by well-known site-directed mutagenesis techniques and employed to generate analogs and derivatives of TIMP-3. Such
35 products would share at least one of the biological

- 17 -

properties of mammalian TIMP-3 but may differ in others. As examples, projected products of the invention include those which are foreshortened by e.g., deletions; or those which are more stable to hydrolysis (and, therefore, may have more pronounced or longer lasting effects than naturally-occurring); or which have been altered to delete one or more potential sites for glycosylation (which may result in higher activities for yeast-produced products); or which have one or more cysteine residues deleted or replaced by, e.g., alanine or serine residues and are potentially more easily isolated in active form from microbial systems; or which have one or more tyrosine residues replaced by phenylalanine and bind more or less readily to target proteins or to receptors on target cells. Also comprehended are polypeptide fragments duplicating only a part of the continuous amino acid sequence or secondary conformations within TIMP-3, which fragments may possess one activity of mammalian TIMP-3 (e.g., immunological activity) and not others (e.g., metalloproteinase inhibiting activity).

The present TIMP-3 may bind to the extracellular matrix, a characteristic not shared by TIMP-1 and TIMP-2. Thus, polypeptides exhibiting only a part of the continuous amino acid sequence or secondary conformations within TIMP-3 possessing the ability to bind to the extracellular matrix are also specifically contemplated herein.

It is noteworthy that activity is not necessary for any one or more of the products of the invention to have therapeutic utility (see, Weiland et al., Blut 44: 173-175 (1982) or utility in other contexts, such as in assays of TIMP-3 antagonism. Competitive antagonists may be quite useful in, for example, cases of overproduction of TIMP-3.

- 18 -

Of applicability to TIMP-3 fragments and polypeptide analogs of the invention are reports of the immunological activity of synthetic peptides which substantially duplicate the amino acid sequence extant in naturally-occurring proteins, glycoproteins and nucleoproteins. More specifically, relatively low molecular weight polypeptides have been shown to participate in immune reactions which are similar in duration and extent to the immune reactions of physiologically significant proteins such as viral antigens, polypeptide hormones, and the like. Included among the immune reactions of such polypeptides is the provocation of the formation of specific antibodies in immunologically active animals. See, e.g., Lerner et al., Cell 23: 309-310 (1981); Ross et al., Nature 294: 654-656 (1981); Walter et al., PNAS-USA 77: 5197-5200 (1980); Lerner et al., PNAS-USA, 78: 3403-3407 (1981); Walter et al., PNAS-USA 78: 4882-4886 (1981); Wong et al., PNAS-USA 79: 5322-5326 (1982); Baron et al., Cell 28: 395-404 (1982); Dressman et al., Nature 295: 185-160 (1982); and Lerner, Scientific American 248: 66-74 (1983). See, also, Kaiser et al. Science 223: 249-255 (1984) relating to biological and immunological activities of synthetic peptides which approximately share secondary structures of peptide hormones but may not share their primary structural conformation.

One type of analog is a truncated TIMP-3 having capacity to bind to the zinc binding domain of collagenase. For example, the zinc binding domain on interstitial collagenase is located at amino acids 218, 222 and 228 at the pro enzyme. Goldberg, G.I., J. Biol. Chem. 261: 660-6605 (1986). The zinc binding domain of the 72 kDa species of procollagenase is located at amino acids 403-407. Collier et al., Genomics 9: 429-434 (1991). The zinc binding domain of the 92 kDa species

- 19 -

of procollagenase is at amino acids 401-405. Van Ranst et al., Cytokine 3: 231-239 (1991). Interestingly, the zinc binding domain is fairly well conserved among enzymes: H E F G H (92 kDa collagenase), H E F G H
5 (72 kDa collagenase) and H E L G H (interstitial collagenase). Thus, the motif for zinc binding is H E X G H wherein X is either F or L. A selective binding molecule, such as an antibody or small molecule would block such zinc binding and therefore inhibit enzymatic
10 activity. (The term "selective binding molecule" as used here indicating a composition which selectively binds to its target.) One may prepare a monoclonal antibody or a recombinant antibody, for example.

TIMP-2 deletion analogs have been prepared
15 which have retained the ability to inhibit metalloproteinase activity. Willenbrock et al., Biochemistry 32: 4330-4337 (1993). For TIMP-2, the C-terminus was shortened to delete six C-terminal cysteines (three disulfide-bonded loops). Thus, in view
20 of the homology among the various zinc binding domains, one could prepare analogous TIMP-3 analogs with similarly shortened C-terminal sequences. The TIMP-3 analog 1-121 (using the numbering of Figure 1 herein) includes the first six cysteines residues, but not the
25 last six. One may optionally lengthen the C-terminus up to the full length molecule of 188 amino acids. Such analogs may also be prepared for any species, such as ChIMP-3.

This is further demonstrated below in the
30 examples, as a TIMP-2 deletion variant is shown to inhibit interstitial collagenase. (Example 3 below). The zinc binding domain of interstitial collagenase is similarly situated as that of the 72 kDa species collagenase (which was shown by Willenbrock et al.,
35 supra, to be affected by the TIMP-2 truncated analogs).

- 20 -

Also, since it is apparent that the C-terminus is not necessary for enzyme inhibition activity, one may chemically modify the C-terminus. One may desire, for example, a sustained release preparation whereby one or
5 more polymer molecules such as polyethylene glycol molecules are attached. Other chemical modifications include attachment of an additional polypeptide for the creation of a fusion molecule. Thus, another aspect of the present invention is chemically modified TIMP-3.

10 The present invention also includes that class of polypeptides coded for by portions of the DNA complementary to the protein-coding strand of the human cDNA or genomic DNA sequences of TIMP-3 i.e., "complementary inverted proteins" as described by
15 Tramontano et al. Nucleic Acid Res. 12: 5049-5059 (1984). Polypeptides or analogs thereof may also contain one or more amino acid analogs, such as peptidomimetics.

Also comprehended by the invention are
20 pharmaceutical compositions comprising effective amounts of polypeptide products of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in TIMP-3 therapy. Such compositions include
25 diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol,
30 benzyl alcohol) and bulking substances (e.g., lactose, mannitol); covalent attachment of polymers such as polyethylene glycol to the protein (as discussed supra,
see, for example U.S. patent 4,179,337 hereby incorporated by reference); incorporation of the
35 material into particulate preparations of polymeric

- 21 -

compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Such compositions will influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of TIMP-3. See,
5 e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by reference.

Generally, an effective amount of the present TIMP-3 polypeptides will be determined by the age,
10 weight and condition or severity of disease of the recipient. See, Remington's Pharmaceutical Sciences, supra, at pages 697-773, herein incorporated by reference. Typically, a dosage of between about 0.001g/kg body weight to about 1g/kg body weight, may be
15 used, but more or less, as a skilled practitioner will recognize, may be used. For local (i.e., non-systemic) applications, such as topical applications, the dosing may be between about 0.001g/cm² to about 1g/cm². Dosing may be one or more times daily, or less frequently, and
20 may be in conjunction with other compositions as described herein. It should be noted that the present invention is not limited to the dosages recited herein.

A plurality of agents act in concert in order to maintain the dynamic equilibrium of the extracellular
25 matrix and tissues. In treatment of conditions where the equilibrium is skewed, one or more of the other agents may be used in conjunction with the present TIMP-3. These other agents may be co-administered or administered in seriatim, or a combination thereof.
30 Generally, these other agents may be selected from the list consisting of the metalloproteinases, serine proteases, inhibitors of matrix degrading enzymes, intracellular enzymes, cell adhesion modulators, and factors regulating the expression of extracellular
35 matrix degrading proteinases and their inhibitors.

- 22 -

While specific examples are listed below, one skilled in the art will recognize other agents performing equivalent functions, including additional agents, or other forms of the listed agents (such as those produced synthetically, via recombinant DNA techniques, and analogs and derivatives).

5 Metalloproteinases and serine proteases degrade the extracellular matrix, as discussed above. Thus, use of enzymes in therapy may be to counteract effects of the present TIMP-3, which inhibits such degradation. Enzymes include collagenases, PMN (polymorphonuclear leukocyte) collagenase, stromelysin I, II/transin, matrilysin, invadolysin, putative metalloproteinase (PUMP-1), urokinase type plasminogen activator (UPA), tissue plasminogen activator (TPA), and plasmin. PD-ECGF may also be used.

Other degradation inhibitors may also be used if increased or more specific prevention of extracellular matrix degradation is desired. Inhibitors may be selected from the group consisting of α_2 macroglobulin, pregnancy zone protein, ovostatin, α_1 -proteinase inhibitor, α_2 -antiplasmin, aprotinin, protease nexin-1, plasminogen activator inhibitor (PAI)-1, PAI-2, TIMP-1, and TIMP-2. Others may be used, as one skilled in the art will recognize.

25 Intracellular enzymes may also be used in conjunction with the present TIMP-3. Intracellular enzymes also may affect extracellular matrix degradation, and include lysozomal enzymes, glycosidases and cathepsins.

30 Cell adhesion modulators may also be used in combination with the present TIMP-3. For example, one may wish to modulate cell adhesion to the extracellular matrix prior to, during, or after inhibition of degradation of the extracellular matrix using the

- 23 -

present TIMP-3. Cells which have exhibited cell adhesion to the extracellular matrix include osteoclasts, macrophages, neutrophils, eosinophils, killer T cells and mast cells. Cell adhesion modulators
5 include peptides containing an "RGD" motif or analog or mimetic antagonists or agonists.

Factors regulating expression of extracellular matrix degrading proteinases and their inhibitors include cytokines, such as IL-1 and TNF- α , TGF- β ,
10 glucocorticoids, and retinoids. Other growth factors effecting cell proliferation and/or differentiation may also be used if the desired effect is to inhibit degradation of the extracellular matrix using the present TIMP-3, in conjunction with such cellular
15 effects. For example, during inflammation, one may desire the maintenance of the extracellular matrix (via inhibition of enzymatic activity) yet desire the production of neutrophils; therefore one may administer G-CSF. Other factors include erythropoietin,
20 interleukin family members, SCF, M-CSF, IGF-I, IGF-II, EGF, FGF family members such as KGF, PDGF, and others. One may wish additionally the activity of interferons, such as interferon alpha's, beta's, gamma's, or consensus interferon. Intracellular agents include
25 G-proteins, protein kinase C and inositol phosphatases. While the field of inflammation research is presently under development, and the precise interactions of the described compositions in vivo is not thoroughly understood, the use of the present polypeptides may
30 provide therapeutic benefit with one or more agents involved in inflammation therapy.

Cell trafficking agents may also be used. For example, inflammation involves the degradation of the extracellular matrix, and the movement, or trafficking
35 of cells to the site of injury. Prevention of

- 24 -

degradation of the extracellular matrix may prevent such cell trafficking. Use of the present TIMP-3 in conjunction with agonists or antagonists of cell trafficking-modulation agents may therefore be desired in treating inflammation. Cell trafficking-modulating agents may be selected from the list consisting of endothelial cell surface receptors (such as E-selectins and integrins); leukocyte cell surface receptors (L-selectins); chemokins and chemoattractants. For a review of compositions involved in inflammation, see Carlos et al., Immunol. Rev. 114: 5-28 (1990), which is herein incorporated by reference.

Moreover, compositions may include neurodifferentiation factor, "NDF," and methods of treatment may include the administration of NDF before, simultaneously with, or after the administration of TIMP-3. NDF has been found to stimulate the production of TIMP-2, and the combination of NDF, TIMP -1, -2 and/or -3 may provide benefits in treating tumors.

Polypeptide products of the invention may be "labeled" by association with a detectable marker substance (e.g., radiolabeled with ¹²⁵I) to provide reagents useful in detection and quantification of TIMP-3 in solid tissue and fluid samples such as blood or urine. Nucleic acid products of the invention may also be labeled with detectable markers (such as radiolabels and non-isotopic labels such as biotin) and employed in hybridization processes to locate the human TIMP-3 gene position and/or the position of any related gene family in a chromosomal map. Nucleic acid sequences which selectively bind the human TIMP-3 gene are useful for this purpose. They may also be used for identifying human TIMP-3 gene disorders at the DNA level and used as gene markers for identifying neighboring genes and their

- 25 -

disorders. Contemplated herein are kits containing such labelled materials.

The TIMP-3 compositions described herein modify the pathogenesis and provide a beneficial therapy
5 for diseases of connective tissues characterized by matrix degradation. Also, the present TIMP-3 compositions may be useful in the treatment of any disorder where excessive matrix loss is caused by metalloproteinase activity. The TIMP-3 compositions may
10 be used alone or in conjunction with one or more of the agents discussed herein.

Polypeptide products of the present invention are useful, alone or in combination with other drugs, in the treatment of various disorders such as dystrophic
15 epidermolysis bullosa where the disease is linked to the overproduction of collagenase, Bauer et al., J. Exp. Med. 148: 1378-1387 (1978). The products of the present invention may also be useful in the treatment of rheumatoid arthritis. Evanson et al. J. Clin. Invest.
20 47: 2639-2651 (1968) noted that large amounts of collagenase are produced, in culture, by excised rheumatoid synovial tissue, this led to immunolocalization studies by Woolley et al., Arthritis and Rheumatism 20: 1231-1239 (1977), with monospecific
25 antibodies directed against human rheumatoid synovial collagenase which detected high levels of immunoreactive collagenase at the sites of joint erosion (cartilagepannus junctions) but not in the cartilage of associated chondrocytes, and not in the synovium at
30 sites remote from the resorbing front. Collagenases have also been demonstrated using many other different preparations derived from human rheumatoid joints and using tissues characterized by other types of arthritis such as osteoarthritis, Reiter's syndrome, pseudogout,
35 juvenile rheumatoid arthritis, and scleroderma.

- 26 -

In periodontal disease affecting the tooth supporting apparatus, elevation of collagenolytic enzymes is evident, and destruction of collagen and connective tissue. See V.-J. Uitto, pp. 211-223 in
5 Proteinases in Inflammation and Tumor Invasion, H. Tschesche, ed., Walter de Gruyter & Co., Berlin, N.Y. (1988).

Collagenases have been implicated in ulceration including corneal, epidermal, or gastric
10 ulceration, Brown et al., American J. of Ophthalmology 72: 1139-1142 (1971), and, indeed, metalloproteinase inhibitors are used in the treatment of corneal ulceration. Slansky et al., Annals of Ophthalmology 2:
488-491 (1970).

15 In wound healing after surgery, TIMP-3 may have particular application for restenosis. Metalloproteinases contribute to the rearrangement of arterial cells, including blockage of the artery. Use of the present TIMP-3 may inhibit such arterial wall
20 rearrangement. Delivery of antisense TIMP-3 nucleic acid may also provide benefit.

In the field of tumor invasion and metastasis, the metastatic potential of some particular tumors correlates with the increased ability to synthesize and
25 secrete collagenases, Liotta et al., Nature 284: 67-68 (1980), and with the inability to synthesize and secrete significant amounts of a metalloproteinase inhibitor, Hicks et al., Int. J. Cancer 33: 835-844 (1984). These processes are related to the passage of tumor cells
30 through connective tissue layers (basement membrane) from tissue sites to the circulation and vice versa, which could be retarded by TIMP-3. TIMP-3 similarly has therapeutic application in inhibiting tumor cell dissemination during removal of primary tumors, during
35 chemotherapy and radiation therapy, during harvesting of

- 27 -

contaminated bone marrow, and during shunting of carcinomatous ascites.

A limiting factor in the use of bone marrow transplantation for many advanced cancers with bone marrow involvement is the absence of adequate purging techniques. For example, metastatic interstitial pneumonitis following infusion of improperly purged bone marrow cells has been noted, Glorieux et al., Cancer 58: 2136-2139 (1986); Graeve et al., Cancer 62: 2125-2127 (1988). TIMP-3 administered during infusion of unpurged bone marrow cells will alleviate the need for developing expensive purging techniques.

Diagnostically, correlation between absence of TIMP-3 production in a tumor specimen and its metastatic potential is useful as a prognostic indicator as well as an indicator for possible prevention therapy.

Tumors may also become more or less encapsulated or fibrotic due to increased collagen deposition (or inhibition of breakdown) by both cancer cells and/or surrounding normal cells. Increased encapsulation promoted by TIMP-3 aids in clean tumor excision.

Other pathological conditions in which excessive collagen degradation may play a role and thus where TIMP-3 can be applied, include emphysema, Paget's disease of bone, osteoporosis, scleroderma, pressure atrophy of bone or tissues as in bedsores, cholesteatoma, and abnormal wound healing. TIMP-3 can additionally be applied as an adjunct to other wound healing promoters, e.g., to modulate the turnover of collagen during the healing process.

TIMP-3 also may have erythroid potentiating activity (i.e., stimulation of differentiation of early erythroid progenitors), and thus TIMP-3 may be useful in the treatment of various anemias.

- 28 -

In addition TIMP-3 may have application in the treatment of immunological disorders such as autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) based upon a potential ability to suppress
5 B-cell differentiation as determined by the method of Pisko et al., J. Immunol. 136: 2141-2150 (1986).

Based on its ability to inhibit connective tissue degradation, TIMP-3 and/or other TIMP molecules have application in cases where inhibition of
10 angiogenesis is useful, e.g., in preventing or retarding tumor development, and the prevention of the invasion of parasites. In addition, the present compositions and methods may be applicable for cosmetic purposes, in that localized inhibition of connective tissue breakdown may
15 alter the appearance of tissue.

The present compositions and methods may also be useful in birth control or fertilization modulation as the TIMPs have been shown to prevent or retard follicular rupture, Branstrom et al., Endocrinology 122:
20 1715-1721 (1988), and interfere with embryo preimplantation development.

The present compositions and methods may be useful in the treatment of nerve cell disorders in that TIMP-3 may protect nerve cells from damage by preserving
25 the basement membrane surrounding nerve cells. Therefore, uses may involve BDNF, NT-3, NGF, CNTF, NDF, SCF, or other nerve cell growth or proliferation modulation factors.

As described above, the present TIMP-3 has
30 wide application in a variety of disorders. Thus, another embodiment contemplated herein is a kit including the present polypeptides and optionally one or more of the additional compositions described above for the treatment of a disorder involving the degradation of
35 extracellular matrix. An additional embodiment is an

- 29 -

article of manufacture comprising a packaging material and a pharmaceutical agent within said packaging material, wherein said pharmaceutical agent contains the present polypeptide(s) and wherein said packaging material comprises a label which indicates that said pharmaceutical agent may be used for an indication selected from the group consisting of: cancer, inflammation, arthritis, dystrophic epidermolysis bullosa, periodontal disease, ulceration, emphysema, bone disorders, scleroderma, wound healing, erythrocyte deficiencies, cosmetic tissue reconstruction, fertilization or embryo implant modulation, and nerve cell disorders. This article of manufacture may optionally include other compositions or label descriptions of other compositions.

The nucleic acids provided herein may also be embodied as part of a kit or article of manufacture. Contemplated is an article of manufacture comprising a packaging material and a pharmaceutical agent, wherein said pharmaceutical agent contains the presently provided nucleic acids and wherein said packaging material comprises a label which indicates that said pharmaceutical composition may be used for an indication benefiting from the modulation of said DNA expression, such as a gene therapy indication. Such gene therapy indications, as discussed above, include the treatment of emphysema. A kit containing the nucleic acid(s) may include, optionally, additional factors affecting the ex vivo growth of recipient cells, such as SCF. See, e.g., Zsebo et al., PCT WO 91/05795, herein incorporated by reference.

A further embodiment of the invention is selective binding molecules, such as monoclonal antibodies specifically binding TIMP-3. The hybridoma technique described originally by Kohler and Milstein

- 30 -

Eur. J. Immunol. 6, 511-519 (1976) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens. Recombinant antibodies, (see Huse et al.,
5 Science 246: 1275 (1989)) may also be prepared. Such antibodies may be incorporated into a kit for diagnostic purposes, for example.

The following examples are offered to more fully illustrate the invention, but are not to be
10 construed as limiting the scope thereof.

EXAMPLE 1

15 Cloning and Expression of Human TIMP-3 cDNA

The overall cloning strategy involved two steps, the first, obtaining a fragment using PCR from a human fetal kidney cDNA library, and the second, using
20 this partial clone to screen two different cDNA libraries for full length cDNA sequences.

Degenerate PCR primers derived from highly conserved regions of the TIMP gene family were used to amplify TIMP-3 cDNA from human fetal kidney cDNA. This
25 product was then used as a probe to isolate clones from a human fetal kidney cDNA library and a normal human colonic mucosa cDNA library. Clones of 1240, 963 and 827 bp have been isolated and sequenced. The longest clone encodes the entire 211 amino acid pro-polypeptide,
30 having a mature polypeptide of 188 amino acids. The intermediate size clone is truncated but encodes the entire mature protein. The smallest clone is missing the region encoding the first 24 amino acids of the mature polypeptide. Also demonstrated is the expression and
35 purification of mature polypeptide.

- 31 -

MATERIALS AND METHODS

Primers and Initial TIMP-3 DNA Source Used

Degenerate PCR primers were used in a first round screening of first strand cDNAs to obtain a partial TIMP-3 cDNA clone. The degenerate PCR primers were derived from highly conserved regions of the TIMP family of proteins were selected, (see Figure 4). They were also chosen because of the relatively low degeneracy of their codons.

The forward primer was derived from a sequence (VIRA) which is ubiquitous throughout the TIMP family and is found at positions 18-21 of the mature proteins. This 96-fold degenerate forward primer had 11 bases that encoded the TIMP sequence plus 6 bases for an *EcoRI* site and 2 extra bases (underlined) 449-15: SEQ. ID No. 1: 5'-CGG AAT TCG TNA THM GNG C-3'

A reverse primer corresponding to a region of ChIMP-3 (CIWTDM) was synthesized. This primer, 480-27, included a *BamHI* site and two extra bases (underlined): SEQ. ID No. 2 5'-CGG GAT CCC ATR TCN GTC CAD ATR CA-3'.

An alternative reverse primer was also used: SEQ. ID No. 3
480-28 CGG GAT CCR TCN GTC CAD ATR CA

The corresponding region is somewhat variant. Amino acids 163-168 of ChIMP-3 are encoded by the version used here, and these were chosen because the M and I distinguished the ChIMP-3 from other TIMPs. It was not initially known if these differences would also be present in human TIMP-3 (if such TIMP did indeed exist), however, a bias away from TIMP-1 and TIMP-2 was used to limit unwanted amplifications. The M at position 168 was especially useful. As a result of its location at

- 32 -

the 5' end of the reverse primer, it would not interfere with the PCR process if there were mismatches and it would favor TIMP-3 amplification over other DNAs if this choice were correct.

5

Amplification of First Strand cDNAs Using Primers

First, the degenerate primers were used to amplify PCR products from the two first strand cDNAs. After a second round of amplification the PCR products of these were subcloned, and one was selected which was used as a probe for cDNA libraries, as described below.

Oligonucleotide synthesis. Oligonucleotides were synthesized on Applied Biosystems 394 automated synthesizers using standard phosphoramidite chemistry. Degenerate oligonucleotides, which were synthesized in greater than 200 nmole quantities, were purified by butanol extraction. Nondegenerate oligonucleotide were synthesized in smaller amounts and were purified Trityl- on using Poly-pak (Glen Research Corp., Sterling, VA) cartridges following the manufacturer's instructions. Trityl-off purification was done using 1 x 25 cm Sephadex G-50 chromatography columns and TEAB as the elution buffer.

Polymerase Chain Reaction. All PCR was performed on Perkin Elmer model 9600 instruments using Perkin Elmer Cetus (Norwalk, CT) GeneAmp kits according to the manufacturer's instructions which are herein incorporated by reference.

The first round of PCR consisted of 5 cycles at 94°C for 20 seconds, 50°C for 20 seconds and 72°C for 30 seconds. This was followed by 30 cycles at 94°C for 20 seconds, 50°C for 20 seconds and 72°C for 30 seconds. The PCR products were run on a 2% agarose (SeaKem GTG, FMC, Rockland, ME) gel, prestained with ethidium bromide

- 33 -

(Sigma, St. Louis, MO), and the bands in the predicted size range were punched out of the gel using a Pasteur pipette. The PCR products were then re-amplified directly from the gel fragments using the same PCR primers and the following program: 1 cycle of 5 minutes at 95°C followed by 25 cycles of 94°C for 20 seconds, 50°C for 20 seconds, and 72°C for 30 seconds. This process was performed a second time in an effort to obtain large quantities of relatively pure material for subcloning and restriction analysis.

First Strand cDNA Sources Oligo dT-primed first strand cDNA from human colonic mucosa (Dr. Gene Finley, Pittsburgh VA Medical Center) as well oligo dT-primed first strand cDNA from 22 week old human fetal kidney (Clontech, Palo Alto, CA) were used as first-round sources of TIMP-3 cDNA. When the colonic mucosa cDNA source was used, the same banding pattern was observed as that observed with the fetal kidney cDNAs, which confirmed those results. These fetal kidney PCR products were then used for subcloning.

Purification and Subcloning of PCR Products. The PCR products were run through Centricon-100 columns (Amicon, Beverly, MA) to facilitate the DNA to be cleaved with restriction endonucleases. The DNA was then cut with *EcoRI* and *BamHI* to ensure that they would not be internally cleaved during the subcloning process. PCR products were cloned into pUC19 after treatment with proteinase K (Crowe et al., 1991) to enhance the cloning efficiency. Colonies were rapidly screened by PCR amplification with vector primers 382-3 SEQ. ID No. 4 (5'-GTT TTC CCA GTC ACG ACG-3') and 382-4 SEQ. ID No. 5 (5'-GAA TTG TGA GCG GAT AAC-3'). These products were purified using Centricon-100 concentrators and were sequenced.

- 34 -

Results. As shown in Figure 2 three bands resulted from amplification with the degenerate primers. Cloned DNA from two of the bands was sequenced; the third band could not be purified sufficiently to allow subcloning and sequencing.

The smaller of the two sequenced bands was the desired 402 bp fragment and the larger band presumably resulted from false priming to the region encoding CSWYRG (amino acids 169-174 of the mature polypeptide of Figure 1) and was 489 bp. The 402 bp fragment corresponds to the nucleic acid encoding the region encompassing ValIleArgAla(Lys) to CysLeuTrpThrAspMet of Figure 1, with an *EcoRI* on the 5' side, and an *BamHI* on the 3' side. Also, the codon for isoleucine on the 3' end is replaced with the codon for leucine.

cdna library screening

Screening of a first cdna library.

Library. The first library screened was an the oligo(dT)-primed λ gt11 Clontech human 20 and 24 week fetal kidney cdna library (Clontech).

Probes. The first round of cdna screening was done with the insert of one of the cloned degenerate PCR products previously described, the 402 bp insert. A low level of background was observed as a result of contamination with pUC19 vector DNA. Consequently, the phage supernatant from a partially purified λ gt11 clone obtained from the first round of cdna screening was used as a PCR template. Friedman et al., Nucl. Acids Res. 17: 8718 (1988). This provided a probe of high quality and purity. The Primer 495-21, SEQ. ID No. 6 5'-CGG AAT TCT GGT CTA CAC CAT CAA GC-3'

- 35 -

corresponded approximately to the YTIK domain and including an *EcoRI* site and two additional bases. Primer 496-16, SEQ. ID No. 7 5'-CAT GTC GGT CCA GAG ACA CTC G-3', corresponded to the CLWTDM region and did not
5 include any restriction sites. This resulted in a 333 bp fragment. The sequence of the 333 bp fragment was a portion of the 402 bp fragment sequence. The 333 bp fragment was used as a probe for all of the northern blot analyses and for all further cDNA library
10 screening. The 333 bp fragment corresponds to the region of Figure 1 encoding TyrThrIleLys through CysLeuTrpThrAspMet and the *EcoRI* site mentioned above.

Plaque Hybridization About 200,000 phage were
15 plated on ten 150 mm plates, lifted in duplicate onto Schleicher & Schuell supported nitrocellulose membranes and probed with a randomly primed, ³²P-labeled (Stratagene) 402 bp fragment described above. Prehybridizations and hybridizations were performed
20 overnight at 42°C using the following reagents (for 50 ml of solution):

	12.5 ml	20X SSPE
	5 ml	0.5 N NaHPO ₄ pH 6.8
25	0.1 ml	0.50 M EDTA pH 8.0
	25 ml	formamide
	2.5 ml	50X Denhardt's
	0.25 ml	20% SDS
	0.5 ml	10 mg/ml tRNA (calf's liver)
30	1 ml	10 mg/ml salmon sperm DNA (not used in the pre-hybridization solution)
	4.15 ml	H ₂ O (3.15 ml used in the hybridization solution)

- 36 -

The filters were washed in 0.25 X SSC at 42°C. Two positively hybridizing plaques were purified, resulting in 2 independent clones here named Timp3clone7 and Timp3clone2. DNA from bacteriophage lambda was
5 purified using a Qiagen Lambda DNA purification kit (Chatsworth, CA). Plate lysates from 10 confluent 135 mm petri dishes were pooled for each specimen. 300 µl of a solution containing 20 mg/ml RNase, 6 mg/ml DNase I, 0.2 mg/ml BSA, 10 mM EDTA, 100 mM Tris-HCl, 300 mM
10 NaCl, pH 7.5 were added and incubated at 37°C for 30 minutes. 10 ml of ice cold 30% polyethylene glycol (PEG 6000), 3 M NaCl were mixed in and incubated on ice for 60 minutes.

After centrifugation at 10,000 x g for 10
15 minutes, the supernatant was discarded. The pellet was resuspended in 10 ml of a solution containing 100 mM Tris-HCl, 100 mM NaCl and 25 mM EDTA, pH 7.5. 10 ml of a solution containing 4% SDS was gently added and the mixture was heated at 70°C for 10 minutes and then
20 cooled on ice. 10 ml of 2.55 M potassium acetate, pH 4.8 was mixed in quickly and the solution was centrifuged at 4°C at 15,000 x g for 30 minutes. The supernatant was run on a Qiagen tip-500 column which had been equilibrated with 10 ml of 750 mM NaCl, 50 mM MOPS,
25 15% ethanol, pH 7.0. The column was then washed with 30 ml 1.0 M NaCl, 50 mM MOPS, 15% ethanol, pH 7.0. Finally, the column was eluted with 15 ml of 1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH 8.2. The eluate was precipitated in 0.7 volumes of isopropanol and
30 centrifuged at 4°C for 30 minutes. The pellet was air dried for 5 minutes and cut with Boehringer Mannheim (Mannheim, Germany) high concentration *EcoRI*.

The inserts which had hybridized to the 333 bp probe were purified from agarose gel slices using a
35 Qiaex DNA extraction kit (Qiagen, Chatsworth, CA). A

- 37 -

solution of 3 M NaI, 4 M NaClO₄, 5 mM Tris-H, pH 7.5 at three times the volume of the gel slice was added, along with 0.1 times the gel slice volume of 1 M mannitol and 10 ml of Qiaex resin in a 1.5 ml microcentrifuge tube.

- 5 This mixture was heated at 50°C for 10 minutes or until the agarose is completely dissolved. The DNA was allowed to adsorb at room temperature for 5 minutes and then the tubes were briefly centrifuged (6 seconds). After the supernatants were discarded, the Qiaex resin
- 10 in the tubes were washed in a solution containing 8 M NaClO₄, and centrifuged (6 seconds). This wash and centrifugation was repeated and was followed by 2 washes (each followed by 6-second centrifugations) in a solution containing 70% ethanol, 100 mM NaCl, 10 mM
- 15 Tris-HCl, 1 mM EDTA, pH 7.5. The resin was air dried and eluted in 20 µl of water.

- The purified inserts were cloned into pUC19 (New England Biolabs) using Boehringer Mannheim's T4 DNA polymerase. There was an insert to vector (molar) ratio
- 20 of approximately 5:1. Ligations were performed overnight at 14°C. The ligated material was ethanol precipitated in the presence of glycogen to increase the recovery. This material was then electroporated into BRL's (Gibco-BRL, Gathersburg, MD) electroporation
- 25 competent DH10B cells.

- Preparations of plasmid DNA were made using using Qiagen plasmid DNA purification kit. A 10 ml overnight culture of a single bacterial colony was grown in terrific broth [Tartoff and Hobbs, Bethesda Res. Lab.
- 30 Focus 2:12 (1987). Per liter: 12 g bacto-tryptone, 24 g bacto-yeast extract, 4 ml glycerol] with 50 µg/ml ampicillin. The overnight growth was used to inoculate a 250 ml culture in a sterile 1-liter baffled flask containing terrific broth with 50 µg/ml ampicillin.
- 35 After this grew to saturation, the medium was

- 38 -

centrifuged at 5000 rpm for 10 minutes. The bacterial pellet was resuspended in 10 ml of 100 µg/ml RNaseA, 50 mM Tris-HCl. 10 ml of 200 mM NaOH, 1% SDS was added to the resuspended pellet and the mixture was incubated at room temperature for 5 minutes. 10 ml of 2.55 M KAc, pH 4.8 was added and mixed gently. The material was immediately centrifuged at 10000 rpm for 10 minutes. The supernatant was filtered through a cotton gauze pad and the lysate that was particle-free was added to a Qiagen tip-500 column following the same procedure as per the lambda DNA preparation procedure.

Screening of a second cDNA library. A cDNA library from human colonic mucosa, kindly provided by Jim Pipas of the University of Pittsburgh, was the second library screened for TIMP-3 cDNA. This library used Uni-Zap (Stratagene, La Jolla, CA) as the vector and had a titer of 2.4×10^{10} pfu/ml. Hybridization was performed as with the kidney library, using the 333 bp probe. The Uni-Zap vector has a pBluescript phagemid which was excised from the phage to which the probes hybridized, and sequenced directly.

Phage particles were isolated and amplified as follows. Phage particles were released into the SM buffer by incubating for 2 hours at room temperature. In a 50 ml test tube, 200 µl of O.D.₆₀₀=1.0 XL1-Blue cells and 200 µl of the lambda Zap phage were combined with 1 ml of R408 helper phage which had a titer of 10^{10} pfu/ml. This mixture was incubated at 37°C for 15 minutes. 3 ml of 2xYT medium (per liter: 16 g bacto-tryptone, 10 g bacto-yeast extract, 5 g NaCl) were added and the mixture was then incubated for 2.5 hours at 37°C with shaking. The tube was heated at 70°C for 20 minutes and then centrifuged at 4000 x g for 5 minutes.

To rescue the phagemid, 50 µl of the heat-disrupted phage stock were incubated with 200 µl of

- 39 -

O.D.600=1.0 XL1-Blue cells in a 1.5 ml tube. .
Additionally, 10 µl of a 10⁻² dilution of heat-disrupted phage were incubated with 200 µl of O.D.600=1.0 XL1-Blue cells in a separate 1.5 ml tube. The tubes were
5 incubated at 37°C for 15 minutes and the cells were then plated on LB ampicillin plates and incubated overnight at 37°C. Colonies appearing on the plate contained the pBluescript SK- double stranded phagemid with the cloned DNA insert.

10 This screening resulted in one clone, here named "TIMP3HCM3," (see Figure 16), lacking a portion encoding the N-terminus of the mature polypeptide.

DNA Sequencing

15

All sequencing was performed on Applied Biosystems, Inc. (ABI) 373A Automated Sequencers. PCR products were sequenced using nested pUC vector dye-primers and ABI's catalyst to perform the reactions.

20

Double stranded cDNAs cloned into pUC19 were sequenced using ABI's Prism Ready Reaction Dye-Deoxy Terminator Cycle Sequencing Kit using the protocol that came with the kit. For areas of high GC content leading to hairpin loops, reactions were done with the following
25 changes from the standard kit protocol: denaturation at 98°C for 30 seconds, 12 U Amplitaq, substitution of New England Biolabs (NEB) Vent Polymerase buffer for the ABI TACS buffer and, 30 cycles instead of 25 cycles.

30 Sequence Analysis

DNA and deduced amino acid analyses used the Genetics Computer Group (GCG) sequence analysis software package from the University of Wisconsin Department of
35 Genetics, Genetic Computer Group, Inc., University

- 40 -

Research Park, 575 Science Drive, Suite B, Madison,
Wisconsin 53711.

Expression of Recombinant Human TIMP-3 in E. coli

5

The coding sequence of Timp3clone7 was amplified by PCR using standard kit protocol. Primer 544-29 SEQ. ID No.8 (5'-AAC AAA CAT ATG TGC ACA TGC TCG CCC AGC C-3') consists of nucleotides 351 to 369, which
10 encodes TIMP-3 amino acids 24-29 (1-6 of the mature protein of Figure 1). An *NdeI* site and 6 extra bases (underlined) were included to facilitate subcloning into a bacterial expression vector. The methionine initiator codon, (*italics*), was added to facilitate expression.
15 The downstream primer, 532-13, SEQ. ID No.9 (5'-CGG GAT CCT ATT AGG GGT CTG TGG CAT TGA TG-3') corresponds to nucleotides 896 to 914 (of Figure 1) with an added *BamHI* site and 2 additional bases (underlined) as well as two stop codons (*italicized*). The naturally occurring stop
20 codon, TGA (TCA on the reverse complement) was changed to TAA (TTA on the reverse complement), since it is a more efficient stop in *E. coli*. The second stop codon, TAG, (CTA on the reverse complement) was added as a backup.

25

The vector pCFM3102, as described below, was digested with *NdeI* and *BamHI* overnight as was the 589 bp PCR fragment encoding TIMP-3. The reaction was stopped by extraction with phenol/chloroform followed by extraction with chloroform alone. The aqueous layer was
30 then passed through a 1 ml Sephadex G-50 spin column (in a 1 ml syringe) that was equilibrated with 200 μ l 10 mM Tris-HCl, 1 mM EDTA pH 8.0. The flow-through from the column was collected and precipitated with 0.1 volumes of 3 M NaAc, pH 5.4 and 2.5 volumes of 100% ethanol.
35 After centrifugation, the pellet was washed in 70%

- 41 -

ethanol and dried in a Speed-Vac (Savant). The pellets were resuspended in 20 µl Super-Q water.

A mock ligation containing cut pCFM3102 with no insert was done in addition the TIMP-3::pCFM3102 ligation. Ligations were performed overnight at 14°C, using Boehringer Mannheim T4 DNA ligase. They were then precipitated, washed and dried as above. The pellets were then resuspended in 5 µl of Super-Q water. 2.5 µl of each ligation was used to electroporate 40 µl of electroporation competent cells.

Electroporation of plasmid into *E. coli* occurred in 0.1 cm cuvettes (Bio-Rad) at 1.9 kV, 200 ohms, 25 µF using a Bio-Rad Gen Pulser and with immediate recovery in 5 ml of SOC medium. The cells recovered at 28°C for 11.3 hours and were plated out onto LB plates containing kanamycin. The plates were incubated at 28°C overnight. Colonies were screened for inserts by PCR using vector-specific primers 315-21 SEQ. ID No. 10 (5'-ACC ACT GGC GGT GAT ACT GAG-3') and 315-22 SEQ. ID No.11 (5'-GGT CAT TAC TGG ACC GGA TC-3'). Colonies having inserts gave PCR products that are 589 bp larger than the PCR product derived from the original vector without an insert.

25 Construction of expression plasmid pCFM3102

Expression of the mature protein was accomplished in *E. coli* using a plasmid vector. A culture of this *E. coli*, containing plasmid encoding a mature polypeptide as presented in Figure 1, is deposited at the ATCC, accession no. _____.

The plasmid used was derived from pCFM836, which is fully described in U.S. Patent No. 4,710,473, herein incorporated by reference. The construction for the present plasmid (denominated pCFM3102) from the described pCFM836 plasmid (U.S. Patent No. 4,710,473) was by destroying the two

- 42 -

endogenous *NdeI* restriction sites, by end filling with T4 polymerase enzyme followed by blunt end ligation, by replacing the DNA sequence between the unique *AatII* and *ClaI* restriction sites containing the synthetic P_L promoter with a similar
5 fragment obtained from pCFM636 (Patent No. 4,710,473) containing the P_L promoter, by substituting the small DNA sequence between the unique *ClaI* and *KpnI* restriction sites with an oligonucleotide containing a number of restriction sites, and by making a series of site directed base changes by
10 PCR overlapping oligonucleotide mutagenesis through the intermediate pCFM1656 vector (4799 base pair).

Fermentation

15 The inoculum for the fermentation was started by transferring 0.1 ml of a glycerol stock at 1 O.D./ml in LB + 17% glycerol of ATCC Accession No. _____ (*E. coli* host cells containing the pCFM3102 with inserted
20 TIMP-3 coding sequences) into a 2-L nipped flask containing 500 ml of Luria Broth (10 g/L Trypticase-Peptone, 10 g/L yeast extract, and 5 g/L sodium chloride). The culture was placed in a shaking platform incubator at 30°C for 16 hours at 250 rpm. The culture
25 was then transferred to 8 liters of sterile medium in a BioLafitte 15-L fermentor.

The 8 liters of medium that were sterilized in place in the fermentor consisted of the following:

30	10 g/L	yeast extract
	5.25 g/L	ammonium sulfate
	3.5 g/L	dibasic potassium phosphate
	4.0 g/L	monobasic potassium phosphate
	1.25 g/L	sodium chloride

35

- 43 -

After the sterilized medium cooled to 30°C the following was added:

	40 g	glucose
5	8 g	magnesium sulfate-heptahydrate
	16 ml	trace metals solution ¹

The pH of the medium was then adjusted to 7.0 using concentrated phosphoric acid. The other parameters of the fermentation during this batch phase were set as follows:

	air flow rate = 31.0 L/min
	agitation = 350 rpm
15	dissolved oxygen readout set at 60%
	oxygen flow rate = 0
	back pressure = 0.5 bar

Once the culture in the fermentation vessel reached at O.D.600 of 6.0, a concentrated solution of glucose and organic nitrogen was started using a schedule that ramps the feed flow according to the O.D. of the culture. This concentrated feed (Feed 1) consisted of the following:

25	50 g/L	Trypticase-peptone
	50 g/L	yeast extract
	450 g/L	glucose
	8.5 g/L	Magnesium-heptahydrate
30	10 ml	trace metals solution ¹
	10 ml	vitamin solution ²

At the time that the concentrated feed was first introduced into the fermentor, the following changes were made:

- 44 -

agitation raised to 850 rpm
back pressure raised to 0.8 bar

- 5 Using the concentrated feed, the O.D. was increased to 30. At that point the culture was induced by raising the temperature to 42°C. Other changes were made as follows:
- 10 air flow rate decreased to 24 L/ min
 oxygen flow rate increased to 3 L/min
 feed 1 decreased to 0
 feed 2 started at 300 ml/hr
- 15 Feed 2 consisted of the following:
 200 g/L Trypticase-peptone
 100 g/L yeast extract
 110 g/L glucose
- 20 After 4 hours at 42°C the fermentation was halted and the cells were harvested by centrifugation into plastic bags contained within a one liter centrifuge bottle. Centrifugation was at 400 rpm for 60 minutes. At the end of this period, the supernatant was
- 25 removed and the remaining cell paste was frozen at -90°C.
- ¹Trace metals solution:
- | | | |
|----|----------|------------------------------------------------------|
| | 27 g/L | FeCl ₃ ·6H ₂ O |
| 30 | 2 g/L | ZnCl ₂ ·4H ₂ O |
| | 2 g/L | CaCl ₂ ·6H ₂ O |
| | 2 g/L | Na ₂ ·MoO ₄ ·2H ₂ O |
| | 1.9 g/L | CuSO ₄ ·5H ₂ O |
| | 0.5 g/L | H ₃ BO ₃ |
| 35 | 100 ml/L | concentrated HCl |

- 45 -

2Vitamin solution:

	0.42 g/L	riboflavin
	5.4 g/L	pantothenic acid
5	6 g/L	niacin
	1.4 g/L	pyridoxine hydrochloride
	0.06 g/L	biotin
	0.04 g/L	folic acid

10 NH₂-terminal amino acid sequencing

NH₂-terminal amino acid sequence of E. coli-
derived recombinant TIMP-3 protein was determined to be
identical to the sequence deduced from the cDNA clones.
15 The methionine initiator from the construct was cleaved
off. There was no other detected proteolytic processing
at the TIMP-3 NH₂-terminus. No assignment was made for
cys-1 and cys-2 since the protein sample was reduced and
reduced cysteines cannot readily be detected by this
20 method. Therefore, the sequence read as follows: X-T-
X-S-P-S-H-P-Q-D-A-F-

Methods

Partially purified recombinant TIMP-3 present
25 in E. coli inclusion bodies was electrophoresed on an
SDS polyacrylamide gel and electroblotted onto a PVDF
membrane for sequence analysis. NH₂-terminal amino acid
analysis was performed on a gas-phase sequenator (model
477, Applied Biosystems, Foster City, CA) according to
30 published protocols. Hewick et al., J. Biol. Chem., 256:
2814-2818 (1981). The sequenator was equipped with an
on-line phenylthiohydantoin (PTH) amino acid analyzer
and a model 900 data analysis system (Hunkapiller et
al., Methods of Protein Microcharacterization, Clifton,
35 NJ: pp. 223-247 (1986)). The PTH-amino acid analysis

- 46 -

was performed with a micro liquid chromatography system (model 120) using dual syringe pumps and reversed phase (C-18) narrow bore columns (Applied Biosystems, Inc.), with the dimensions of 2.1 mm x 240 mm.

5

Protein Purification

Approximately 435 g wet weight of *E. coli* cell paste, harvested from the fermentation run was resuspended to a volume of 1760 ml in water and broken by two passes through a microfluidizer. The cell lysate was centrifuged at 17,700 x g for 30 min, and the pellet fraction was washed once with water (by resuspension and by recentrifugation). A portion of the washed pellet material (3.1% of the total) was resuspended in 10 ml of 50 mM Tris-HCl/50 mM dithiothreitol/2% (w/v) sodium N-lauroylsarcosine, pH 8.5. After incubation at 50°C for 5 min, and at room temperature for 3 hr, the mixture was centrifuged at 20,000 x g for 60 min. The supernatant was applied to a Sephacryl S-200 gel filtration column (Pharmacia; 2 x 23 cm) equilibrated in 20 mM Tris-HCl/1% sodium N-lauroylsarcosine, pH 8.0, at room temperature. Fractions of 1 ml were collected at a flow rate of 5 ml/hr and analyzed by A₂₈₀ and by SDS/polyacrylamide gel electrophoresis (PAGE). Fractions 43-53 were pooled, and the pool was dialyzed over a 3-day period against 20 mM Tris-HCl (pH 8.0), 0.02 % (w/v) sodium azide, at 4°C.

Figure 3 presents a silver stained SDS-PAGE gel of the partially purified expression product from this fermentation. Lanes 3 and 4 contain reduced *E. coli* derived TIMP-3, pre- and post- dialysis. Lanes 9 and 10 contain unreduced *E. coli* derived TIMP-3, pre- and post- dialysis. As can be seen, the apparent

- 47 -

molecular weight for reduced material is approximately 22kDa.

As can be seen from Figure 3, the post-dialysis yield was reduced; the polypeptide appeared to be somewhat unamenable to solubilization. In the present process, the presence of inclusion bodies containing relatively insoluble material resulted in a reduced yield of purified and isolated TIMP-3. Although this resulted in a partially purified product, one skilled in the art will recognize methods to obtain a purified and isolated polypeptide. For example, one may use different detergents as solubilizing agents, or use a different expression system, for example, one which permits secretion of the polypeptide (and thus elimination of inclusion bodies).

Expression and purification was also attempted using eucaryotic cells (COS-7 cells), however no active recombinant TIMP-3 polypeptide was observed. This may have been due to adherence of the recombinant TIMP-3 polypeptide to extracellular matrix material produced by COS-7 cells. One possible way to obtain active protein from a mammalian host cell may be to use cells which are non-adherent, and therefore produce no significant amount of extracellular matrix material. The recombinant polypeptide would then be found in the conditioned culture medium. For example Jurkat cells or U937 cells may be used for recombinant polypeptide expression, and other non-adherent host cells and expression systems will be apparent to those skilled in the art.

30

Results of Screening Two cDNA Libraries and Expression of Recombinant Human TIMP-3

The work herein presents the cloning and expression of a third class of mammalian TIMP family members, herein collectively referred to as "TIMP-3".

35

- 48 -

The nucleotide sequence obtained from a human fetal kidney cDNA library is presented in Figure 1. Seq. ID No. 12 As can be seen, the nucleic acid sequence obtained contains 1240 base pairs. The predicted amino acid sequence is also presented. Seq. ID No. 13 (The amino acid sequence is predicted, as the polypeptide itself was not fully sequenced. One skilled in the art may sequence the expression product of the *E. coli* deposited at the ATCC, accession no. ____). The predicted initial cysteine of the mature protein is number +1. This prediction is based upon comparison to other members of the TIMP family.

Figure 4 presents this comparison among the known members of the TIMP family. Bullet points (•) indicate those amino acid residue which are unique to the TIMP-3 of Figure 1 obtained from expression of human cDNA, and bold-face type indicates conserved residues.

As can be see, the present human recombinant TIMP-3 of Figure 1 is distinct from all other members of the TIMP family. While possessing the conserved cysteine residues and other conserved amino acids within the family (39, total), at least 23 amino acid residues are unique to the illustrated human recombinant TIMP-3.

Figures 5-13 illustrate the differences between the present human recombinant TIMP-3 of Figure 1 and chicken TIMP-3 ("ChIMP-3," Figures 5-7), human TIMP-2 (Figures 8-10), and human TIMP-1 (Figures 11-13), at both the amino acid and nucleic acid levels. The Figures contain a solid line between amino acid residues which are identical, and dots indicating the degree of evolutionary distance. (For Figures 5, 8, and 11, illustrating amino acid alignment, the numbering at position "1" is for the mature polypeptide.)

At the amino acid level, TIMP-3 and ChIMP-3 are approximately 80% identical, with identical amino

- 49 -

acids being more or less dispersed discontinuously, (Figure 5). Figure 6 shows that, at the nucleic acid level, Figure 1 TIMP-3 DNA is approximately 74% homologous with ChIMP-3 DNA, between nucleic acids 151-1087 (TIMP-3) and 1-886 (ChIMP-3). Figure 7 shows that even analyzing the region of maximal homology, base pairs 282-1040 from Figure 1 TIMP-3, and 113-884 for ChIMP-3), there is approximately 78% identity.

Figures 8-10 illustrate a comparison between human recombinant TIMP-3 of Figure 1 and human TIMP-2. At both the amino acid level and the nucleic acid level, there are greater distinctions than with ChIMP-3. Figure 8 shows that there is approximately 46% identity at the amino acid level. Figure 9 shows that, at the nucleic acid level, the overall homology is approximately 52% overall, and approximately 60% in the region of maximal homology (Figure 10).

Figures 11-13 illustrate a comparison between human recombinant TIMP-3 of Figure 1 and human TIMP-1. At the amino acid level, there is approximately 39% identity (Figure 11), and approximately 47% overall homology at the nucleic acid level. There is approximately 65% identity in the region of maximal homology.

Biochemically, the calculated isoelectric points (pI) of the mature TIMP-3 polypeptide and its pre-cursor are 9.16 and 8.80, respectively. There is a potential glycosylation site at the carboxy-terminal sequence (184:NAT). While naturally occurring ChIMP-3 is reported to be non-glycosylated (Pavloff et al., supra, J. Biol. Chem. 267: at 17323), it is not currently known whether naturally occurring human TIMP-3 is glycosylated. Regardless, the present invention includes polypeptides with additional chemical moieties, such as carbohydrates. The hydrophobic leader of the

- 50 -

Figure 1 material is 23 amino acids long. Sequencing of the N-terminus confirmed the identity of the first 12 amino acids of the mature recombinant polypeptide.

The cloning and expression described herein demonstrates that the present TIMP-3 polypeptides represent new members in the TIMP family.

EXAMPLE 2

10 Expression of TIMP-3 In Various Cell Types

A variety of cells were tested for the expression of TIMP-3 RNA (which would indicate polypeptide expression). The results show that among
15 normal (i.e., non-cancerous) cells, expression is observed in cells associated with extracellular matrix activity (i.e., growth or degradation). The normal cells (or tissues) where TIMP-3 RNA expression was seen (Figures 14A and B) are placenta, stromal cells,
20 embryonic lung, newborn foreskin (one of two samples being slightly positive), and (slightly positive) adult lung. Among the cancer cells tested, some were positive, some were negative. For example, various breast adenocarcinoma cell lines yielded disparate
25 results; with one was positive, one was negative, one was slightly positive. This may indicate temporal expression, in that TIMP-3 expression may vary over the course of disease progression, although the significance is unclear. Table 2, below, presents a description of
30 the cells tested and the results. Below are the methods.

- 51 -

In many of the positive cell lines three mRNA bands of approximate 2.2, 2.5 and 4.4 kb size were detected. The significance of the different mRNA bands
5 is unknown but may represent alternative splicing or extended 3' or 5' untranslated regions. These may be RNAs encoding different naturally occurring variants.

TABLE 1
MATRIX-degrading metalloproteinases

Name(s)	Size (kDa)	Degrades	Ref.
(1) Interstitial collagenase (Type I collagenase) (MMP-1)	52 deduced 52, 57 secreted	I, II, III collagen	Scholz et al., Cancer Res. 48:5539-5545 (1988)
PMN Collagenase (MMP-8)	75 secreted	I, II, III collagen	Macartney et al., Eyr. J. Biochem. 130: 71-78 (1983).
(2) 72 kDa Type IV collagenase (72 kDa gelatinase) (MMP-2)	72 secreted	IV, V, VII collagen, fibronectin, gelatins	Collier et al., J. Biol. Chem. 263:6579-6587 (1988)
92 kDa Type IV collagenase (92 kDa gelatinase) (MMP-9)	78 deduced 92 secreted	IV, V collagen, gelatins	Wihelm et al., J. Biol. Chem. 263: 17213-17221 (1989)
(3) Stromelysin (transin) (proteoglycanase) (procollagen-activating factor) (MMP-3)	53 deduced 57, 60 secreted	Proteoglycans, laminin, fibronectin, III, IV, V collagen, gelatins	Chin et al., J. Biol. Chem. 260: 12367-12376 (1985)
Stromelysin-2 (transin-2) (MMP-10)	53 deduced	III, IV, V collagen, fibronectin, gelatins	Nicholson et al., Biochemistry 28: 5195-5203 (1989)
PUMP-1 (MMP-7) (Small metalloproteinase of uterus)	28 deduced 28 secreted	Gelatins, fibronectin	Qumtin et al., Biochemistry 28: 5327-5333 (1989)

The matrix metalloproteinases are divided into three major subclasses, indicated with arabic numerals, on the basis of their substrate specificities. The enzymes in each class are bold, and alternative names are shown in parentheses. MMP, matrix metalloproteinase; PMN, polymorphonuclear leukocyte.

- 53 -

Methods

Two types of Northern blots were performed, one on total RNA transcripts, and one using poly A+ tailed transcripts.

5

Total RNA Preparation. Total RNA for the total RNA northern was extracted from cells using a modification of a published protocol (Chomczynski and Sacchi, Anal. Biochem. 162: 156-159 (1987)).

10

Cells grown in 2 x 10cm petri dishes (approximately 2×10^6 cells), were washed two times with cold 1x PBS. After all of the PBS was aspirated off, 500 μ l of an aqueous solution containing the following was added to each dish: 4 M guanidinium thiocyanate (Fluka), 25 mM sodium citrate pH 7.0 (Mallinckrodt), 0.5% sarcosyl (Sigma, St. Louis, MO) 0.1M β -mercaptoethanol (Sigma, St. Louis, MO). The cell lysate was pipetted into a 1.5 ml Eppendorf microfuge tube and was sheared with a 25 gauge needle.

15

20

Sodium acetate (pH 4) was added to the 500 μ l lysate to make a final concentration of 0.2 M. The mixture was shaken vigorously by hand. 1/5 volume of chloroform was added and mixed thoroughly. The tubes were spun at 15,000 rpm for 5 minutes at 20°C in a Tomy MTX-100 centrifuge. The tubes were inverted to allow the white precipitate layer to separate from the aqueous layer instead of respinning. The RNA was re-extracted with phenol and chloroform two additional times and was extracted one final time with chloroform. 1 ml of isopropanol was added to the microfuge tube and the mixture was precipitated at -20°C overnight. The next day it was spun at 15,000 rpm for 15 minutes. The pellet was washed with 1 volume of 80% ethanol, re-spun, and dried in a Speed Vac (Savant, Farmingdale, NY).

25

30

- 54 -

The pellet was resuspended in 400 μ l of the guanidinium solution which contained β -mercaptoethanol (Sigma, St. Louis, MO). 800 μ l of ethanol was added to this mixture, which was then spun at 15,000 rpm for 15 minutes and washed with 80% ethanol. This pellet was resuspended in 20 μ l of water and the O.D. was determined.

Poly A+ RNA Preparation. Poly A+ RNA was prepared using Clontech (Palo Alto, CA) oligo dT-cellulose spun columns. 2 x 1 ml of a high salt buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.5 M NaCl) was washed through the columns and drained by gravity. Total RNA, isolated as described above, was resuspended in 1 ml of elution buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA) and was heated at 68°C for 3 minutes. 0.2 ml of sample buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 3M NaCl) was added to the RNA solution, which was then placed on ice.

The samples were loaded onto the freshly equilibrated columns and allowed to soak under gravity. The columns were placed inside 50 ml tubes and were centrifuged at 350 x g for 2 minutes. The eluates were discarded. 0.25 ml of the high salt buffer (see above) was added to each column and the columns were centrifuged at 350 x g for 2 minutes. This wash was repeated once. In each case, the eluates were discarded. The columns were then washed 3 times with low salt buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.1 M NaCl) and centrifuged each time at 350 x g for 2 minutes. The eluates were discarded in each instance. Sterile 1.5 ml microcentrifuge tubes were placed inside of the 50 ml tubes to collect subsequent elutions. 0.25 ml of elution buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA,) warmed to 65°C were applied to the columns, which were then spun at 350 x g for 2 minutes. This procedure

- 55 -

was repeated 3 times for a total of 4 elutions per column. For each column, all of the elutions were collected in a microcentrifuge tube. The eluents were ethanol precipitated as above.

5

Northern Blotting. 10 µg of total RNA was loaded in each lane. The sample buffer included 10 µl of formamide, 3.5 µl of formaldehyde, 2 µl of 10x MOPS, 2 µl of loading dye, 0.2 µl of ethidium bromide, and 6.5 µl of RNA sample in water. The poly A+ RNA blot had 3 µg of mRNA loaded in each lane.

10 The gels for the northern blots consisted of 1.5 g of agarose melted in 95 ml of water and then cooled to 60°C. 30 ml of 5x MOPS and 25 ml of formaldehyde (pH 4.7) were added to the cooling agarose solution. Prior to transfer, the gels were trimmed to remove excess gel. They were then soaked in distilled water for 5 minutes, followed by a 10 minute soak in 50 mM NaOH, 10 mM NaCl at room temperature. The gels were neutralized in 0.1 M Tris-HCl, pH 7.5 for 45 minutes and then soaked in 20X SSC for 1 hour. Transfer occurred overnight in 10X SSC. The gels were blotted onto Schleicher & Scheull (Keene, NH) nitrocellulose membranes. The total RNA gel was blotted onto pure nitrocellulose and fixed by UV crosslinking using a Stratalink (Stratagene, La Jolla, CA). The poly A+ gel was blotted onto supported nitrocellulose and was baked in a vacuum oven for 2 hours at 80°C.

25 The blots were hybridized in a manner similar to the screening of the cDNA library. The sole difference is that for the northern blot analysis, RNase-free reagents were used wherever possible.

30

- 56 -

EXAMPLE 3

In Vitro Activity of Human Recombinant TIMP-3Modified Zymogram

5 DeClerck et al. J. Biol. Chem. 266: 17445-17453 (1991) showed that TIMP-2 will bind to pAPMA-activated rabbit fibroblast interstitial collagenase in complexes that are stable in SDS. The 52 kDa inactive presursor was cleaved to an active 42 kDa protein by the
10 organomercurial. Although the active protein primarily degrades type I, II and III collagen, it will also degrade gelatin to a lesser degree.

Conditioned medium (CM) from rabbit synovial fibroblasts contains interstitial collagenase as well as
15 72 kDa type IV gelatinase. The CM was incubated in 5 μ l of 50 mM Tris-HCl, 200 mM NaCl, 10 mM CaCl₂, pH 7.5 for 15 minutes in either the presence or absence of TIMP-2 (according to EP 0 398 753), TIMP-2 Δ or the Figure 1 TIMP-3. Note that TIMP-2 Δ refers to a truncated
20 biologically active form of TIMP-2 with amino acids 128-194 of the mature protein deleted. Tolley et al., J. Mol. Biol. 229: 1163-1164 (1993); Willenbrock et al., Biochemistry 32: 4430-4437 (1993). It has previously been shown that TIMP-2 interacts preferentially with 72
25 kDa procollagenase but that these complexes were not stable in 0.1% (w/v) SDS. Stetler-Stevenson, J. Biol. Chem., 264: 17374-17378 (1989). The TIMP-3 tested was the dialyzed TIMP-3 of Figure 3.

In the absence of TIMPs, 2 zones of clearing
30 are visible when CM from rabbit synovial fibroblasts is run on a 10% acrylamide, 0.1% gelatin gel. Figure 15. One of the bands corresponds to 42 kDa pAPMA-activated interstitial collagenase. This clearing was absent in the presence of CM incubated with TIMP-2, TIMP2 Δ , or the
35 Figure 1 TIMP-3. The other zone of clearing was not

- 57 -

affected, meaning that it did not form as SDS-stable complex with the TIMP. In a separate experiment using the present methods (data not shown) a zone of clearing generated by the collagenase in medium conditioned by COS-7 cells was not inhibited by the presence of TIMP-2, TIMP-2Δ or TIMP-3.

EXAMPLE 4

10. Preparation of TIMP-3 Polypeptide Analogs and Nucleic Acid Variants

The amino acid sequence of full length TIMP-3 is presented in Figure 1. Using the numbering of Figure 1, the full length sequence is 188 amino acids long. The amino acid sequence at -23 through -1 is a leader sequence, and thus the pro version of the polypeptide is 211 amino acids in length.

The coding region of the TIMP-3 DNA of Figure 1 is -69 through position 564 of the nucleic acid sequence illustrated.

Alternatively, for either variant, one may construct a signal peptide sequence for eucaryotic cell expression. As can be seen from Figure 16, two additional cDNA clones have been isolated, TIMP3clone2. Seq. ID Nos. 14, 15 (ATCC Accession No. ____) and TIMP3HCM-3 Seq. ID Nos. 16, 17 (ATCC Accession No. ____). These clones represent natural variants. Timp3clone2 lacks part of the region encoding the N-terminus of the leader sequence of TIMP3clone7. As such, this would be preferably expressed in a procaryote, such as *E. coli*. TIMP3HCM-3 lacks a portion of the region encoding the NH₂-terminus of the mature protein. Since this clone lacks the hydrophobic leader sequence, it would be preferably expressed in a procaryote, such as *E. coli*.

- 58 -

Figure 16 shows that there are some differences among the three cDNA clones. At nucleotide 320, there is an A in TIMP3clone 2 and a T in TIMP3clone 7. This would result in a change in the amino acid sequence from a *trp* to an *arg* at position 14 in the hydrophobic leader sequence. This difference may be a cloning artifact due to its location at the 5' end of that clone. ChIMP-3 also has a *trp* at this position. Another divergence can be found at base 529, in which clone 2 has a C and clones 7 and HCM-3 have a T. This polymorphism does not result in an amino acid change because both CAT and CAC encode *his*. Other polymorphisms are found in or near the poly A tail. The poly A tail of HCM-3 is preceded by a single G, whereas in the other 2 clones it is preceded by GG. The poly A tail of clone 7 is 15 bases long and the poly A tail of HCM-3 is 18 bases long. The poly A tail of clone 2 is 17 bases long, is interrupted by 3 other bases, and is followed by 32 nucleotides of additional 5' untranslated sequence.

PCR product 29 (TIMP3PCR29 Seq. ID Nos. 18, 19, see Figure 16) was also obtained from the human fetal kidney cDNA screening, using one insert specific primer and one vector specific primer as follows:

Seq. ID No. 7 (496-16) (CLWTDM forward):
5'- CGG AAT TCT GTC TCT GGA CCG ACA TGC TCT CC 3'
Seq. ID No.20 (489-23) (lambda gt11 reverse):
5' GAC ACC AGA CCA ACT GGT AAT G 3'

As can be seen from Figure 16, this may represent a naturally occurring C-terminal variant. At Figures 16B, bottom, to 16C, top, differences in amino acid sequence between TIMP3clone7 and TIMP3PCR29 are indicated. TIMP3PCR29, cloned into pUC19 and placed into *E. coli* has been deposited at the ATCC with accession no. _____. A full cDNA clone encompassing

- 59 -

this PCR product has not been found in the fetal kidney cDNA library, however. It is unknown if TIMP3PCR29 represents a full or partial variant or a PCR artifact.

Other TIMP-3 analogs may be prepared. One
5 type of analog is a truncated form which exhibits
binding to the portion of a metalloproteinase which
binds zinc. As indicated supra, the conserved region
for this zinc binding domain may be represented by H E X
G H, wherein X is either F or L. By analogy to TIMP-2
10 deletion analogs which have been prepared, TIMP-3
analogs maintaining enzyme inhibition activity may also
be prepared.

Figure 17 is an illustration of the proposed
secondary structure for the TIMP family of proteins. See
15 Alexander et al., Extracellular Matrix Degradation, in,
Cell Biology of Extracellular Matrix (2d ed., Hay, ed.),
Plenum Press, New York, pp. 255-302. As can be seen,
the six C-terminal cysteines form a secondary structure
which is somewhat separate from the structure formed by
20 the region encompassing the first six cysteines.
Previously, TIMP-2 analogs lacking the C-terminus up to
and including the 6th cysteine in from the C-terminus
have been shown to have activity. Willenbrock et al.,
Biochemistry 32: 4330-4337 (1993). TIMP-3 analogs
25 lacking one or more of the C-terminal cysteines are
those having the sequence (referring to the numbering of
Figure 1) of 1-121, and any of 1-122 through 1-188.
Additions, deletions, and substitutions may also be made
to amino acids 122-188, as well as attachment of
30 chemical moieties, such as polymers.

While the present invention has been described
in terms of preferred embodiments, it is understood that
variations and modifications will occur to those skilled
35 in the art. Therefore, it is intended that the appended

- 60 -

claims cover all such equivalent variations which come within the scope of the invention as claimed.

- 61 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: AMGEN INC.
- (ii) TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type
Three (TIMP-3) Composition and Methods
- (iii) NUMBER OF SEQUENCES: 21
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Amgen Inc./Patent Operations/KMP
 - (B) STREET: 1840 Dehavilland Drive
 - (C) CITY: Thousand Oaks
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 91320-1789
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGGAATTCGT NATHMGNGC

19

- 62 -

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGGGATCCCA TRTCNGTCCA DATRCA

26

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGGGATCCRT CNGTCCADAT RCA

23

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTTTTCCCAG TCACGACG

18

- 63 -

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GAATTGTGAG CGGATAAC

18

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGGAATTCTG GTCTACACCA TCAAGC

26

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CATGTCGGTC CAGAGACACT CG

22

- 64 -

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AACAAACATA TGTGCACATG CTCGCCCAGC C

31

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGGGATCCTA TTAGGGGTCT GTGGCATTGA TG

32

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ACCACTGGCG GTGATACTGA G

21

- 65 -

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGTCATTACT GGACCGGATC

20

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1240 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGCGGCGGGC GCTCAGACGG CTTCTCCTCC TCCTCTTGCT CCTCCAAGCT CCTGCTCCTT	60
CGCCGGGAGC CCGCCCGCCG AGTCCTGCGC CAGCGCCGAG GCAGCCTCGC TGCGCCCAT	120
CCCGTCCCGC CGGGCACTCG GAGGGCAGCG CGCCGGAGGC CAAGGTTGCC CCGCACGGCC	180
CGGCGGGCGA GCGAGCTCGG GCTGCAGCAG CCCC GCCGGC GCGCGCACG GCAACTTTGG	240
AGAGGCGAGC AGCAGCCCCG GCAGCGGCGG CAGCAGCGGC AATGACCCCT TGGCTCGGGC	300
TCATCGTGCT CCTGGGCAGC TGGAGCCTGG GGGACTGGGG CGCCGAGGCG TGCACATGCT	360
CGCCAGCCA CCCCAGGAC GCCTTCTGCA ACTCCGACAT CGTGATCCGG GCCAAGGTGG	420
TGGGAAGAA GCTGGTAAAG GAGGGGCCCT TCGGCACGCT GGTCTACACC ATCAAGCAGA	480
TGAAGATGTA CCGAGGCTTC ACCAAGATGC CCCATGTGCA GTACATCCAT ACGGAAGCTT	540
CCGAGAGTCT CTGTGGCCTT AAGCTGGAGG TCAACAAGTA CCAGTACCTG CTGACAGGTC	600
GCGTCTATGA TGGCAAGATG TACACGGGGC TGTGCAACTT CGTGGAGAGG TGGGACCAGC	660
TCACCTCTC CCAGCGCAAG GGGCTGAACT ATCGGTATCA CCTGGGTTGT AACTGCAAGA	720

- 66 -

TCAAGTCCTG CTACTACCTG CCTTGCTTTG TGACTTCCAA GAACGAGTGT CTCTGGACCG 780
 ACATGCTCTC CAATTTTCGGT TACCCTGGCT ACCAGTCCAA ACACTACGCC TGCATCCGGC 840
 AGAAGGGCGG CTACTGCAGC TGGTACCGAG GATGGGCCCC CCCGGATAAA AGCATCATCA 900
 ATGCCACAGA CCCCTGAGCG CCAGACCTG CCCCACCTCA CTTCCCTCCC TTCCCGCTGA 960
 GCTTCCCTTG GACACTAACT CTTCCAGAT GATGACAATG AAATTAGTGC CTGTTTTCTT 1020
 GCAAATTTAG CACTTGGAAC ATTTAAAGAA AGGTCTATGC TGTCATATGG GGTTTATTGG 1080
 GAACTATCCT CCTGGCCCCA CCCTGCCCCT TCTTTTGGT TTTGACATCA TTCATTTCCA 1140
 CCTGGGAATT TCTGGTGCCA TGCCAGAAAG AATGAGGAAC CTGTATTCCT CTTCTTCGTG 1200
 ATAATATAAT CTCTATTTTT TTAGGAAAAA AAAAAAAAAA 1240

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 211 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met	Thr	Pro	Trp	Leu	Gly	Leu	Ile	Val	Leu	Leu	Gly	Ser	Trp	Ser	Leu	1	5	10	15
Gly	Asp	Trp	Gly	Ala	Glu	Ala	Cys	Thr	Cys	Ser	Pro	Ser	His	Pro	Gln	20	25	30	
Asp	Ala	Phe	Cys	Asn	Ser	Asp	Ile	Val	Ile	Arg	Ala	Lys	Val	Val	Gly	35	40	45	
Lys	Lys	Leu	Val	Lys	Glu	Gly	Pro	Phe	Gly	Thr	Leu	Val	Tyr	Thr	Ile	50	55	60	
Lys	Gln	Met	Lys	Met	Tyr	Arg	Gly	Phe	Thr	Lys	Met	Pro	His	Val	Gln	65	70	75	80
Tyr	Ile	His	Thr	Glu	Ala	Ser	Glu	Ser	Leu	Cys	Gly	Leu	Lys	Leu	Glu	85	90	95	

- 67 -

Val Asn Lys Tyr Gln Tyr Leu Leu Thr Gly Arg Val Tyr Asp Gly Lys
 100 105 110

Met Tyr Thr Gly Leu Cys Asn Phe Val Glu Arg Trp Asp Gln Leu Thr
 115 120 125

Leu Ser Gln Arg Lys Gly Leu Asn Tyr Arg Tyr His Leu Gly Cys Asn
 130 135 140

Cys Lys Ile Lys Ser Cys Tyr Tyr Leu Pro Cys Phe Val Thr Ser Lys
 145 150 155 160

Asn Glu Cys Leu Trp Thr Asp Met Leu Ser Asn Phe Gly Tyr Pro Gly
 165 170 175

Tyr Gln Ser Lys His Tyr Ala Cys Ile Arg Gln Lys Gly Gly Tyr Cys
 180 185 190

Ser Trp Tyr Arg Gly Trp Ala Pro Pro Asp Lys Ser Ile Ile Asn Ala
 195 200 205

Thr Asp Pro
 210

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 963 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CAGGAGCCTG GGGGACTGGG GCGCCGAGGC GTGCACATGC TCGCCCAGCC ACCCCCAGGA 60

CGCCTTCTGC AACTCCGACA TCGTGATCCG GGCCAAGGTG GTGGGGAAGA AGCTGGTAAA 120

GGAGGGGCCC TTCGGCACGC TGGTCTACAC CATCAAGCAG ATGAAGATGT ACCGAGGCTT 180

CACCAAGATG CCCCATGTGC AGTACATCCA CACGGAAGCT TCCGAGAGTC TCTGTGGCCT 240

TAAGCTGGAG GTCAACAAGT ACCAGTACCT GCTGACAGGT CGCGTCTATG ATGGCAAGAT 300

GTACACGGGG CTGTGCAACT TCGTGGAGAG GTGGGACCAG CTCACCCTCT CCCAGCGCAA 360

GGGGCTGAAC TATCGGTATC ACCTGGGTTG TAACTGCAAG ATCAAGTCCT GCTACTACCT 420

GCCTTGCTTT GTGACTTCCA AGAACGAGTG TCTCTGGACC GACATGCTCT CCAATTTTCG 480

- 68 -

```

TTACCCTGGC TACCAGTCCA AACACTACGC CTGCATCCGG CAGAAGGGCG GCTACTGCAG   540
CTGGTACCGA GGATGGGCCC CCCCGGATAA AAGCATCATC AATGCCACAG ACCCCTGAGC   600
GCCAGACCCT GCCCCACCTC ACTTCCCTCC CTCCCCGCTG AGCTTCCCTT GGACACTAAC   660
TCTTCCCAGA TGATGACAAT GAAATTAGTG CCTGTTTTCT TGCAAATTTA GCACTTGGAA   720
CATTTAAAGA AAGGTCTATG CTGTCATATG GGGTTTATTG GGAACATATC TCCTGGCCCC   780
ACCCTGCCCC TTCTTTTTGG TTTTGACATC ATTCATTTCC ACCTGGGAAT TTCTGGTGCC   840
ATGCCAGAAA GAATGAGGAA CCTGTATTCC TCTTCTTCGT GATAATATAA TCTCTATTTT   900
TTTAGGAAAA CAAAAATGAA AACTACTCC ATTTGAGGAT TGTAATTTCC AACACCACCT   960
GCT

```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 198 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Arg Ser Leu Gly Asp Trp Gly Ala Glu Ala Cys Thr Cys Ser Pro Ser
1           5           10           15
His Pro Gln Asp Ala Phe Cys Asn Ser Asp Ile Val Ile Arg Ala Lys
20           25           30
Val Val Gly Lys Lys Leu Val Lys Glu Gly Pro Phe Gly Thr Leu Val
35           40           45
Tyr Thr Ile Lys Gln Met Lys Met Tyr Arg Gly Phe Thr Lys Met Pro
50           55           60
His Val Gln Tyr Ile His Thr Glu Ala Ser Glu Ser Leu Cys Gly Leu
65           70           75           80
Lys Leu Glu Val Asn Lys Tyr Gln Tyr Leu Leu Thr Gly Arg Val Tyr
85           90           95

```

- 69 -

Asp Gly Lys Met Tyr Thr Gly Leu Cys Asn Phe Val Glu Arg Trp Asp
 100 105 110
 Gln Leu Thr Leu Ser Gln Arg Lys Gly Leu Asn Tyr Arg Tyr His Leu
 115 120 125
 Gly Cys Asn Cys Lys Ile Lys Ser Cys Tyr Tyr Leu Pro Cys Phe Val
 130 135 140
 Thr Ser Lys Asn Glu Cys Leu Trp Thr Asp Met Leu Ser Asn Phe Gly
 145 150 155 160
 Tyr Pro Gly Tyr Gln Ser Lys His Tyr Ala Cys Ile Arg Gln Lys Gly
 165 170 175
 Gly Tyr Cys Ser Trp Tyr Arg Gly Trp Ala Pro Pro Asp Lys Ser Ile
 180 185 190
 Ile Asn Ala Thr Asp Pro
 195

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 820 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGAAGAAGC TGGTAAAGGA GGGGCCCTTC GGCACGCTGG TCTACACCAT CAAGCAGATG 60
 AAGATGTACC GAGGCTTCAC CAAGATGCCC CATGTGCAGT ACATCCATAC GGAAGCTTCC 120
 GAGAGTCTCT GTGGCCTTAA GCTGGAGGTC AACAAAGTACC AGTACCTGCT GACAGGTCGC 180
 GTCTATGATG GCAAGATGTA CACGGGGCTG TGCAACTTCG TGGAGAGGTG GGACCAGCTC 240
 ACCCTCTCCC AGCGCAAGGG GCTGAACTAT CGGTATCACC TGGGTTGTAA CTGCAAGATC 300
 AAGTCCTGCT ACTACCTGCC TTGCTTTGTG ACTTCCAAGA ACGAGTGTCT CTGGACCGAC 360
 ATGCTCTCCA ATTTGCGTTA CCCTGGCTAC CAGTCCAAAC ACTACGCCTG CATCCGGCAG 420
 AAGGGCGGCT ACTGCAGCTG GTACCGAGGA TGGGCCCCC CGGATAAAAG CATCATCAAT 480
 GCCACAGACC CCTGAGCGCC AGACCCTGCC CCACCTCACT TCCCTCCCTT CCCGCTGAGC 540

- 70 -

TTCCCTTGA CACTAACTCT TCCCAGATGA TGACAATGAA ATTAGTGCCT GTTTTCTTGC 600
 AAATTTAGCA CTTGGAACAT TTAAAGAAAG GTCTATGCTG TCATATGGGG TTTATTGGGA 660
 ACTATCCTCC TGGCCCCACC CTGCCCTTC TTTTGGTTT TGACATCATT CATTTCACC 720
 TGGGAATTTT TGGTGCCATG CCAGAAAGAA TGAGGAACCT GTATTCCTCT TCTTCGTGAT 780
 AATATAATCT CTATTTTTTT AGAAAAAAAA AAAAAAAAAA 820

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 164 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Gly Lys Lys Leu Val Lys Glu Gly Pro Phe Gly Thr Leu Val Tyr Thr
 1 5 10 15
 Ile Lys Gln Met Lys Met Tyr Arg Gly Phe Thr Lys Met Pro His Val
 20 25 30
 Gln Tyr Ile His Thr Glu Ala Ser Glu Ser Leu Cys Gly Leu Lys Leu
 35 40 45
 Glu Val Asn Lys Tyr Gln Tyr Leu Leu Thr Gly Arg Val Tyr Asp Gly
 50 55 60
 Lys Met Tyr Thr Gly Leu Cys Asn Phe Val Glu Arg Trp Asp Gln Leu
 65 70 75 80
 Thr Leu Ser Gln Arg Lys Gly Leu Asn Tyr Arg Tyr His Leu Gly Cys
 85 90 95
 Asn Cys Lys Ile Lys Ser Cys Tyr Tyr Leu Pro Cys Phe Val Thr Ser
 100 105 110
 Lys Asn Glu Cys Leu Trp Thr Asp Met Leu Ser Asn Phe Gly Tyr Pro
 115 120 125
 Gly Tyr Gln Ser Lys His Tyr Ala Cys Ile Arg Gln Lys Gly Gly Tyr
 130 135 140

Cys Ser Trp Tyr Arg Gly Trp Ala Pro Pro Asp Lys Ser Ile Ile Asn
145 150 155 160

(2) INFORMATION FOR SEQ ID NO:18:

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CTCTGGACCG ACATGCTCTC CAATTCGGT TACCCTGGCT ACCAGTCAA AACTACACA 60
TGCTCGCCCA GCCACCCCG CACGCGCTCC CG 92

(2) INFORMATION FOR SEQ ID NO:19:

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Leu Trp Thr Asp Met Leu Ser Asn Phe Gly Tyr Pro Gly Tyr Gln Ser
1 5 10 15

Lys His Tyr Thr Cys Ser Pro Ser His Pro Arg Thr Arg Ser Thr
20 25 30

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 72 -

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GACACCAGAC CAACTGGTAA TG

22

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CGGAATTCTG TCTCTGGACC GACATGCTCT CC

32

- 73 -

WHAT IS CLAIMED IS:

1. Purified and isolated mammalian TIMP-3.
- 5 2. Human TIMP-3 free of association with other human protein.
3. A purified and isolated polypeptide having part or all of the primary structure of mammalian
10 TIMP-3 as presented in Figure 1, and at least one of the biological properties of mammalian TIMP-3.
4. A polypeptide according to claim 3 wherein said biological property is the inhibition of a
15 metalloproteinase.
5. A polypeptide according to claim 3 wherein said biological property is the binding to the extracellular matrix material.
20
6. A polypeptide according to claim 3 wherein said polypeptide is the product of procaryotic or eucaryotic expression of an exogenous DNA sequence.
- 25 7. A polypeptide according to claim 6 wherein said exogenous DNA sequence is a cDNA sequence.
8. A polypeptide according to claim 6 wherein said exogenous DNA sequence is a genomic DNA
30 sequence.
9. A polypeptide according to claim 6 wherein said polypeptide is recombinant human
35 TIMP-3.

- 74 -

10. A polypeptide according to claim 6 wherein said exogenous DNA sequence is carried on an autonomously replicating DNA plasmid or viral vector.

5 11. A purified and isolated polypeptide having the amino acid sequence presented in Figure 1.

12. A purified and isolated polypeptide having the amino acid sequence of amino acids 1-188 as presented in Figure 1, optionally having a methionyl residue at position -1.

10

13. A polypeptide according to claims 1, 2 or 3 further characterized by being covalently associated with a detectable label substance.

15

14. An isolated DNA sequence for use in securing expression in a procaryotic or eucaryotic host cell of a polypeptide product having an amino acid sequence sufficiently duplicative of that of mammalian TIMP-3 to allow possession of a metalloproteinase inhibition activity of mammalian TIMP-3, said DNA sequence selected from among:

20

25 (a) the DNA sequence set forth in Figure 1 (and complementary strands);

(b) a DNA sequence which hybridizes to the DNA in Figure 1, wherein said hybridization conditions are those allowing detection of human TIMP-3 cDNA using a ChIMP-3 DNA probe or more stringent conditions;

30

(c) a DNA sequence of subpart (b) which, but for the degeneracy of the genetic code, would hybridize to the DNA in Figure 1; or

35

- 75 -

(d) a fragment of the DNA sequences of subpart (a), (b) or (c) above which is at least long enough to selectively hybridize to human genomic DNA
5 encoding TIMP-3.

15. A procaryotic or eucaryotic host cell transformed or transfected with a DNA sequence according to claim 14 in a manner allowing the host cell to
10 express said polypeptide product.

16. A polypeptide product of expression of a DNA sequence of claim 14 in a procaryotic or eucaryotic host cell.
15

17. A vector containing the DNA sequence according to claim 14.

18. A vector according to claim 17 wherein
20 said vector is a plasmid vector.

19. A vector according to claim 17 wherein said vector is a viral vector.

25 20. A vector according to claim 19 wherein said viral vector is selected from the group consisting of a bacteriophage vector, a retroviral vector, and an adenoviral vector.

30 21. A composition containing a DNA sequence according to claim 14 and a pharmaceutically acceptable carrier.

- 76 -

22. A composition of claim 21 wherein said carrier is selected from the group consisting of a lipid solution carrier, a liposome, and a polypeptide.

5 23. A cDNA sequence according to claim 14.

24. A genomic DNA sequence according to claim 14.

10 25. A DNA sequence according to claim 14 which encodes human TIMP-3.

15 26. An antisense DNA with respect to the DNA according to claim 14.

27. A DNA sequence according to claim 14, the expression of which is optimized by the inclusion of one or more codons preferred for expression in bacterial cells.

28. A DNA sequence according to claim 14 the expression of which is optimized by the inclusion of one or more codons preferred for expression in mammalian cells.

29. A DNA sequence according to claim 14 the expression of which is optimized by the inclusion of one or more codons preferred for expression in yeast cells.

30 30. A DNA sequence according to claim 14 covalently associated with a detectable label substance.

- 77 -

31. A DNA sequence as set forth in Figure 1
or Figure 16, said sequence encoding at least amino
acids 1-188 as set forth in Figure 1, and optionally
encoding an additional methionyl residue at the -1
5 position.

32. A procaryotic or eucaryotic host cell
transformed or transfected with a DNA sequence according
to claim 31 in a manner allowing the host cell to
10 express said polypeptide product.

33. A polypeptide product of expression of a
DNA sequence of claim 31 in a procaryotic or eucaryotic
host cell.
15

34. A vector containing the DNA sequence
according to claim 31.

35. A vector according to claim 34 wherein
20 said vector is a plasmid vector.

36. A vector according to claim 34 wherein
said vector is a viral vector.

25 37. A vector according to claim 36 wherein
said viral vector is selected from the group consisting
of a bacteriophage vector, a retroviral vector, and an
adenoviral vector.

30 38. A composition containing a DNA sequence
according to claim 31 and a pharmaceutically acceptable
carrier.

- 78 -

39. A composition of claim 38 wherein said carrier is selected from the group consisting of a lipid solution carrier, a liposome, and a polypeptide.

5 40. An antisense DNA with respect to the DNA sequence according to claim 31.

10 41. A DNA sequence according to claim 31, the expression of which is optimized by the inclusion of one or more codons preferred for expression in bacterial cells.

15 42. A DNA sequence according to claim 31 the expression of which is optimized by the inclusion of one or more codons preferred for expression in mammalian cells.

20 43. A DNA sequence according to claim 31 the expression of which is optimized by the inclusion of one or more codons preferred for expression in yeast cells.

 44. A DNA sequence according to claim 31 covalently associated with a detectable label substance.

25 45. The host cell selected from the group consisting of those with ATCC designations (Timp3clone7/pCFM, Timp3clone7/puC19, Timp3clone2/puC19, Timp3HCM3, Timp3PCR29) __, __, __, __, and __.

30 46. A process for the production of TIMP-3 comprising: growing, under suitable conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA according to claim 14 or 31, and isolating desired polypeptide products of the expression
35 of said DNA sequences.

- 79 -

47. A pharmaceutical composition comprising purified and isolated human TIMP-3 in a pharmaceutically acceptable diluent, adjuvant or carrier.

5

48. An article of manufacture comprising a packaging material and a pharmaceutical agent, wherein said pharmaceutical agent contains human TIMP-3 and wherein said packaging material comprises a label which
10 indicates that said pharmaceutical agent may be used for an indication selected from the group consisting of cancer, inflammation, arthritis, dystrophic epidermolysis bullosa, periodontal disease, ulceration, emphysema, bone disorders, scleroderma, wound healing,
15 erythrocyte deficiencies, cosmetic tissue reconstruction, fertilization or embryo implant modulation and nerve cell disorders.

49. A kit containing a preparation of human
20 TIMP-3 and one or more additional compositions beneficial for the treatment of a disorder involving the degradation of extracellular matrix.

50. A kit of claim 49 wherein said additional
25 composition is selected from the group consisting of: metalloproteinases, serine proteases, inhibitors of matrix degrading enzymes, intracellular enzymes, cell adhesion modulators, and factors regulating the expression of extracellular matrix degrading proteinases
30 and their inhibitors.

51. A kit of claim 50 wherein said additional composition is selected from the group consisting of collagenases, PMN collagenase, stromelysin I,

- 80 -

II/transin, matrilysin, invadolysin, PUMP-1, UPA, TPA, and plasmin.

52. A kit of claim 50 wherein said additional
5 composition is selected from the group consisting of α_2 -
macroglobulin, pregnancy zone protein, ovostatin, α_1 -
proteinase inhibitor, α_2 -antiplasmin, aprotinin,
protease nexin-1, PAI-1, PAI-2, TIMP-1 and TIMP-2.
- 10 53. A kit of claim 50 wherein said additional
composition is selected from the group consisting of
lysosomal enzymes, glycosidases and cathepsins.
- 15 54. A kit of claim 50 wherein said additional
composition is a cell adhesion modulator.
- 20 55. A kit of claim 50 wherein said additional
composition is a factor regulating expression of
extracellular matrix degrading proteinases and their
inhibitors.
- 25 56. A kit of claim 50 wherein said additional
composition is selected from the group consisting of an
interleukin, $\text{TNF}\alpha$, $\text{TGF-}\beta$, glucocorticoids, retinoids,
EPO, SCF, M-CSF, IGF-I, IGF-II, EGF, an FGF, KGF, PDGF,
an interferon, protein kinase C, and inositol
phosphatases.
- 30 57. A kit of claim 49 wherein said additional
composition is selected from the group consisting of E-
selectins, integrins, L-selectins, chemokines, and
chemoattractants.

- 81 -

58. A kit of claim 49 wherein said additional composition is selected from the group consisting of BDNF, NT-3, NGF, CNTF, and NDF.

5 59. A method of treating conditions characterized by extracellular matrix degradation in a mammal comprising administering an effective amount of the polypeptide according to claim 1.

10 60. A method according to claim 59 wherein said condition is selected from the group consisting of cancer, inflammation, arthritis, dystrophic epidermolysis bullosa, periodontal disease, ulceration, emphysema, bone disorders, scleroderma, wound healing,
15 erythrocyte deficiencies, cosmetic tissue reconstruction, fertilization or embryo implant modulation and nerve cell disorders.

20 61. A method of treating a lung disorder characterized by undue extracellular matrix degradation in a mammal comprising administering to the lungs of said mammal an effective amount of a DNA encoding human TIMP-3.

25 62. A method according to claim 61 wherein said disorder is emphysema.

30 63. A method of treating emphysema in a mammal comprising administering to the lungs of said mammal an effective amount of a DNA encoding human TIMP-3, said DNA optionally within a vector or associated with a pharmaceutically acceptable carrier.

35 64. An article of manufacture comprising a packaging material and a pharmaceutical agent, wherein

- 82 -

said pharmaceutical agent contains a DNA encoding human TIMP-3 and wherein said packaging material comprises a label which indicates that said pharmaceutical composition may be used for an indication benefitting from genetic therapy using such DNA.

65. An article of manufacture of claim 64 wherein said indication is emphysema.

66. A kit including a DNA encoding human TIMP-3 and one or more additional factors affecting the ex vivo growth of cells transformed or transfected with said DNA.

67. A kit of claim 66 including SCF.

68. Anti-human TIMP-3 antibody.

69. A kit containing an anti-human TIMP-3 antibody.

70. A selective binding molecule prepared against the amino acid sequence H E X G H where X is either F or L.

71. A mature human TIMP-3 polypeptide as set forth in Figure 1, optionally having a methionyl residue at position -1, lacking one or more of the six C-terminal cysteine residues.

72. A human TIMP-3 polypeptide as set forth in Figure 1, optionally having a methionyl residue at position -1, having the amino acid sequence 1-121 and optionally all or part of amino acids 122-188.

- 83 -

73. A human TIMP-3 polypeptide of claim 72 having the capacity to bind the zinc binding domain of collagenase.

5 74. A human TIMP-3 polypeptide of claim 72 having a chemical modification located at one or more of amino acids 122-188.

1/26

FIG. 1

GGCGGCGGGCGCTCAGACGGCTTCTCCTCCTCCTCTTGCTCCTCCAAGCTCCTGCTCCTT	60
CGCCGGGAGCCCGCCGCGAGTCCTGCGCCAGCGCCGAGGCAGCCTCGCTGCGCCCAT	120
CCCGTCCCCCGGGGCACTCGGAGGGCAGCGCGCCGAGGCCAAGGTTGCCCCGACGGCC	180
CGGCGGGCGAGCGAGCTCGGGCTGCAGCAGCCCCGCGGGCGCGCACGGCAACTTTGG	240
AGAGGCGAGCAGCAGCCCCGGCAGCGGGCGGCAGCAGCGGCAATGACCCCTTGGCTCGGGC	300
MetThrProTrpLeuGlyLeu	-17
-23	
TCATCGTGCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGCGCCGAGGCGTGACATGCT	360
IleValLeuLeuGlySerTrpSerLeuGlyAspTrpGlyAlaGluAlaCysThrCysSer	4
-1 +1	
CGCCAGCCACCCCGAGGACGCTTCTGCAACTCCGACATCGTGATCCGGGCCAAGGTGG	420
ProSerHisProGlnAspAlaPheCysAsnSerAspIleValIleArgAlaLysValVal	24
TGGGGAAGAAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGGTCTACACCATCAAGCAGA	480
GlyLysLysLeuValLysGluGlyProPheGlyThrLeuValTyrThrIleLysGlnMet	44
TGAAGATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCTT	540
LysMetTyrArgGlyPheThrLysMetProHisValGlnTyrIleHisThrGluAlaSer	64
CCGAGAGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAGGTC	600
GluSerLeuCysGlyLeuLysLeuGluValAsnLysTyrGlnTyrLeuLeuThrGlyArg	84
GCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACCAGC	660
ValTyrAspGlyLysMetTyrThrGlyLeuCysAsnPheValGluArgTrpAspGlnLeu	104
TCACCCTCTCCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTTGTAAGTCAAGA	720
ThrLeuSerGlnArgLysGlyLeuAsnTyrArgTyrHisLeuGlyCysAsnCysLysIle	124
TCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCG	780
LysSerCysTyrTyrLeuProCysPheValThrSerLysAsnGluCysLeuTrpThrAsp	144
ACATGCTCTCCAATTTTCGGTTACCCTGGCTACCAGTCCAAACACTACGCCTGCATCCGGC	840
MetLeuSerAsnPheGlyTyrProGlyTyrGlnSerLysHisTyrAlaCysIleArgGln	164
AGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCGGATAAAAGCATCATCA	900
LysGlyGlyTyrCysSerTrpTyrArgGlyTrpAlaProProAspLysSerIleIleAsn	184
ATGCCACAGACCCCTGAGCGCCAGACCCTGCCCCACCTCACTTCCCTCCCTTCCCCGCTGA	960
AlaThrAspProEnd	188
GCTTCCCTTGGACACTAACTCTTCCCAGATGATGACAATGAAATTAGTGCCTGTTTTCTT	1020
GCAATTTAGCACTTGGAACATTTAAAGAAAGGTCTATGCTGTCATATGGGGTTTATTTGG	1080
GAATATCCTCCTGGCCCCACCCTGCCCCCTCTTTTTGGTTTTGACATCATTCATTTCCA	1140
CCTGGGAATTTCTGGTGCCATGCCAGAAAGATGAGGAACCTGTATTCTCTTCTTCGTG	1200
ATAATATAATCTCTATTTTTTTTAGGAAAAAAAAAAAAAAAAA	1240

2/26




FIG. 2

3/26




FIG. 3

4/26

FIG. 4

	-23		1		24
Bovine TIMP-1	...MAPFAPM	ASGILLLLWL	TAPSRA[CTCV	PPHPQTAFCN	SDVVIRAKFV
Human TIMP-1	...MAPFEPL	ASGILLLLWL	IAPSRA[CTCV	PPHPQTAFCN	SDLVIRAKFV
Rabbit TIMP-1	...MAPLAAL	ASSMLLLWL	VAPSRA[CTCV	PPHPQTAFCN	SDLVIRAKFV
Mouse TIMP-1	..MMAPFASL	ASGILLLLSL	IASSKA[CSCA	PPHPQTAFCN	SDLVIRAKFM
Bovine TIMP-2	MGAAARSLPL	AFCLLLGLTL	LPRADA[CSCS	PVHPQQAFCN	ADIVIRAKAV
Human TIMP-2	MGAAARTLRL	ALGLLLLATL	LPRADA[CSCS	PVHPQQAFCN	ADVIRAKAV
Mouse TIMP-2	MGAAARSLRL	ALGLLLLASL	VRPADA[CSCS	PVHPQQAFCN	ADVIRAKAV
Chick TIMP-3	MTAWLGFLAV	FLCSWSLRDL	..VAEA[CTCV	PIHPQDAFCN	SDIVIRAKVV
Human TIMP-3	MTPWLGLI.V	LLGSWSLGDW	..GAEA[CTCS	PSHPQDAFCN	SDIVIRAKVV
	25	***			65
Bovine TIMP-1	GTAEVNETAL	Y.....QR	YEIKMTKMFK	GFSALRDAPD	IRFIYTPAME
Human TIMP-1	GTPEVNQTTL	Y.....QR	YEIKMTKMYK	GFQALGDAAD	IRFVYTPAME
Rabbit TIMP-1	GAPEVNHTTL	Y.....QR	YEIKTTKMFK	GFDALGHATD	IRFVYTPAME
Mouse TIMP-1	GSPEINETTL	Y.....QR	YKIKMTKMLK	GFKAVGNAAD	IRYAYTPVME
Bovine TIMP-2	NKKEVDSGND	IYGNPIKRIQ	YEIKQIKMFK	GPDQ.....D	IEFIYTAPAA
Human TIMP-2	SEKEVDSGND	IYGNPIKRIQ	YEIKQIKMFK	GPEK.....D	IEFIYTAPSS
Mouse TIMP-2	SEKEVDSGND	IYGNPIKRIQ	YEIKQIKMFK	GPDK.....D	IEFIYTAPSS
Chick TIMP-3	GKKLMKDG..PFGTMR	YTVKQMKMYR	GFQIM...PH	VQYIYTEASE
Human TIMP-3	GKKLVKEG..PFGTLV	YTIKQMKMYR	GFTKM...PH	VQYIHTASE
	66	***			113
Bovine TIMP-1	SVCGYFHRSQ	NRSEEFLLIAG	QLSNGHLHIT	TCSFVAPWNS	MSSAQRGFT
Human TIMP-1	SVCGYFHRSQ	NRSEEFLLIAG	KLQDGLLHIT	TCSFVAPWNS	LSLAQRGFT
Rabbit TIMP-1	SVCGYSHKSQ	NRSEEFLLIAG	QLRNGLLHIT	TCSFVVPWNS	LSFSQRSGFT
Mouse TIMP-1	SLCGYAHKSQ	NRSEEFLLITG	RLRNGNLHIS	ACSFVVPWRT	LSPAQQRAFS
Bovine TIMP-2	AVCGVSLDIG	GKKEYLIAGK	AEGNGNMHIT	LCDFIVPWDT	LSATQKKSLN
Human TIMP-2	AVCGVSLDVG	GKKEYLIAGK	AEGDGKMHIT	LCDFIVPWDT	LSTTQKKSLN
Mouse TIMP-2	AVCGVSLDVG	GKKEYLIAGK	AEGDGKMHIT	LCDFIVPWDT	LSITQKKSLN
Chick TIMP-3	SLCGVKLEV.	NKYQYLITGR	VY.EGKVYTG	LCNWEYKWR	LTLQKRGKLN
Human TIMP-3	SLCGLKLEV.	NKYQYLLTGR	VY.DGKMYTG	LCNFERWDQ	LTLQKRGKLN
	114				162
Bovine TIMP-1	KTYAAGCEEC	TVFPCLSSIPC	KLQSDTHCLW	TDQLLTGSDK	GFQSRHLACL
Human TIMP-1	KTYTVGCEEC	TVFPCLSSIPC	KLQSGTHCLW	TDQLLQSEK	GFQSRHLACL
Rabbit TIMP-1	KTYAAGCDMC	TVFACASIPC	HLESPTHCLW	TDSSL.GSDK	GFQSRHLACL
Mouse TIMP-1	KTYSAGCGVC	TVFPCLSSIPC	KLESPTHCLW	TDQVLVGSE.	DYQSRHFACL
Bovine TIMP-2	HRYQMGE.C	KITRCMPIPC	YISSPDECLW	MDWVTEKNIN	GHQAKFFACI
Human TIMP-2	HRYQMGE.C	KITRCMPIPC	YISSPDECLW	MDWVTEKNIN	GHQAKFFACI
Mouse TIMP-2	HRYQMGE.C	KITRCMPIPC	YISSPDECLW	MDWVTEKSIN	GHQAKFFACI
Chick TIMP-3	HRYHLGCG.C	KIRPCYYLPC	FATSKNECIW	TDMLSNFGHS	GHQAKHYACI
Human TIMP-3	YRYHLGCN.C	KIKSCYYLPC	FVTSKNECLW	TDMLSNFGYP	GYQSKHYACI
	163		188		
Bovine TIMP-1	PREPGLCTWQ	SLRAQMA...			
Human TIMP-1	PREPGLCTWQ	SLRSQIA...			
Rabbit TIMP-1	PQEPGLCAWE	SLRPRKD...			
Mouse TIMP-1	PRNPGLCTWR	SLGAR.....			
Bovine TIMP-2	KRSDGSCAWY	RGAAPPKQEF	LDIEDP		
Human TIMP-2	KRSDGSCAWY	RGAAPPKQEF	LDIEDP		
Mouse TIMP-2	KRSDGSCAWY	RGAAPPKQEF	LDIEDP		
Chick TIMP-3	QRVEGYCSWY	RGWAPPDKTI	INATDP		
Human TIMP-3	RQKGGYCSWY	RGWAPPDKSI	INATDP		

SUBSTITUTE SHEET (RULE 26)

5/26

FIG. 5

```

TIMP-3      1 MTPWLGLI.VLLGSWSLGDWGAEACTCSPSHPODAFCNSDIVIRAKVVGK 49
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
ChIMP-3     1 MTAWLGFLAVFLCSWSLRDLVAEACTCVPIHPQDAFCNSDIVIRAKVVGK 50
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
TIMP-3      50 KLVKEGPFGLVYTIKQMKMYRGFTKMPHVQYIHTEASESLCGLKLEVNK 99
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
ChIMP-3     51 KLMKDGPFGTMRYTVKQMKMYRGFQIMPHVQYIYTEASESLCGVKLEVNK 100
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
TIMP-3      100 YQYLLTGRVYDGKMYTGLCNFVERWDQLTSLQKGLNRYRYHLGCNCKIKS 149
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
ChIMP-3     101 YQYLITGRVYEGKVYTGLCNWYEKWDRLTSLQKGLNRYRYHLGCGCKIRP 150
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
TIMP-3      151 CYYLPCFVTSKNECLWTDMLSNGFGYPGYQSKHYACIRQKGGYCSWYRGWA 200
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
ChIMP-3     150 CYYLPCFATSKNECIWTDMLSNGFGHSGHQAKHYACIQRVEGYCSWYRGWA 199
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
TIMP-3      200 PPDKSIINATDP 211
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||
ChIMP-3     201 PPDKTIINATDP 212
              ||:|||::: |:|.|||| |:| ||||| | ||||| ||||| ||||| |||||

```

SUBSTITUTE SHEET (RULE 26)

6/26

FIG. 6A

TIMP-3 151 CGCCGAGAGGCCAAGGTTGCCCCGCACGGCCCGCGGGCGAGCGAGCTCGG 200
ChIMP-3 1CGCGAGAGAGAGGCGGTGTGAGGAGGGAGCGAGCGAGCAGCG 42

TIMP-3 201 GCTGCAGCAGCCCCGCCGGCGCGCGCACGGCAACTTTGGAGAGGCGAGC 250
ChIMP-3 43 AACAGGCGAGGCTCGAGTTAGGCGAACAGAACAGCGGCTGCAGCTCGAAG 92

TIMP-3 251 AGCAGCCCCGGCAGCGGGCGGCAGCAGCGGCAATGACCCCTTGGCTCGG... 298
Chimp-3 393 CGCACCCCGGG.....GCAGGCAGCATGACGGCGTGGCTCGGCT 131

TIMP-3 299 .GCTCATCGTGCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGCGCCGAG 347
ChIMP-3 132 TCCTCGCCGTGTTCTGTGCAGCTGGAGCCTGCGGGACCTGGTGGCGGAG 181

TIMP-3 348 GCGTGACATGCTCGCCCAGCCACCCCAAGGACGCCTTCTGCAACTCCGA 397
ChIMP-3 182 GCGTGCACTTGCGTCCCCATCCACCCGACAGGACGCGTTCTGCAACTCCGA 231

TIMP-3 398 CATCGTGATCCGGGCCAAGGTGGTGGGGAAGAAGCTGGTAAAGGAGGGGC 447
Chimp-3 232 CATCGTGATCCGTGCTAAAGTTGTGGGGAAGAAGCTCATGAAAGATGGAC 281

TIMP-3 448 CCTTCGGCACGCTGGTCTACACCATCAAGCAGATGAAGATGTACCGAGGC 497
ChIMP-3 282 CATTTGGAACAATGCGATACACAGTCAAGCAGATGAAGATGTACAGGGGC 331

TIMP-3 498 TTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCTTCCGAGAG 547
ChIMP-3 332 TTCCAGATAATGCCACACGTTTACGTACATCTACACAGAAGCCTCAGAGAG 381

TIMP-3 548 TCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAG 597
ChIMP-3 382 TCTTTGTGGTGTGAAACTGGAGGTCAACAAATACCAGTATCTGATTACAG 431

TIMP-3 598 GTCGCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAG 647
ChIMP-3 432 GCCGCGTGTACGAAGGGAAGGTTTACACTGGCCTGTGCAATTGGTATGAG 481

TIMP-3 648 AGGTGGGACCAGCTCACCTCTCCCAGCGCAAGGGGCTGAACTATCGGTA 697
ChIMP-3 482 AAATGGGACCGACTGACTCTGTCCCAGCGTAAAGGACTGAATCATCGTTA 531

TIMP-3 698 TCACCTGGGTTGTAAGTCAAGATCAAGTCCTGCTACTACCTGCCTTGCT 747
ChIMP-3 532 TCATCTGGGCTGTGGATGCAAGATTTCGGCCCTGCTACTATTTGCCCTGCT 581

SUBSTITUTE SHEET (RULE 26)

7/26

FIG. 6B

```

TIMP-3  748 TTGTGACTTCCAAGAACGAGTGTCTCTGGACCGACATGCTCTCCAATTTTC 797
      |||  ||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
ChIMP-3  582 TTGCCACCTCCAAGAATGAGTGCATTTGGACAGACATGCTCTCCAACCTTC 631

TIMP-3  798 GGTTACCCTGGCTACCAAGTCCAAACACTACGCCTGCATCCGGCAGAAGGG 847
      ||  ||  ||  ||  |||||  ||  ||  |||||  |||||  |||||  ||  ||  ||
ChIMP-3  632 GGCCACTCAGGACACCAAGCGAAGCACTATGCCTGCATCCAGAGGGTGGA 681

TIMP-3  848 CGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCCCCGGATAAAAGCATCA 897
      ||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
ChIMP-3  682 AGGTTACTGCAGCTGGTATAGAGGATGGGCGCCTCCAGATAAAACGATCA 731

TIMP-3  898 TCAATGCCACAGACCCCTGAGCGC.CAGACCCTGCCCCACCT..CACTTC 944
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
ChIMP-3  732 TCAATGCCACAGATCCCTGAGCACGCTGTACCTTCCTTATCTTCCCTCTC 781

TIMP-3  945 CCTCCCTTCCCGCTGAGCTTCCCTTGGACACTAACTCTTCCC.....AG 988
      |||  |||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
ChIMP-3  782 CCTTACTTGTGGCTGATCTTCCTTTGGACACTAACTCTTACCCGATCATG 831

TIMP-3  989 ATGATGACAATGAAATTAGTGCCTGTTTTCTTGCAAATT.TAGCACTTGG 1037
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
ChIMP-3  832 ATGATGACAATGAAATTAGTGCCTGTTTTCTTGCAAATTCTAGCACTTCG 881

TIMP-3  1038 AACATTTAAAGAAAGGTCTATGCTGTCATATGGGGTTTATTGGGAACATAT 1087
      |||
ChIMP-3  882 AACCG..... 886

```

SUBSTITUTE SHEET (RULE 26)

8/26

TIMP-3	282	ATGACCCCTTGGCTCGGGCTCAT...CGTGTCTCCTGGGCAGCTGGAGCCT	328
ChIMP-3	113	ATGACGGCGTGGCTCGGCTTCCTCGCCGTGTTCCTGTGCAGCTGGAGCCT	162
TIMP-3	329	GGGGGACTGGGGCGCCGAGGCGTGCACATGCTCGCCAGCCACCCCAGG	378
ChIMP-3	163	GCGGGACCTGGTGGCGGAGGCGTGCACCTGCGTCCCCATCCACCCGAGG	212
TIMP-3	379	ACGCCTTCTGCAACTCCGACATCGTGATCCGGGCCAAGGTGGTGGGGAAG	428
ChIMP-3	213	ACGCGTTCTGCAACTCCGACATCGTGATCCGTGCTAAAGTTGTGGGGAAG	262
TIMP-3	429	AAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGGTCTACACCATCAAGCA	478
ChIMP-3	263	AAGCTCATGAAAGATGGACCATTGGAACAATGCGATACACAGTCAAGCA	312
TIMP-3	479	GATGAAGATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCC	528
ChIMP-3	313	GATGAAGATGTACAGGGGCTTCAGATAATGCCACACGTTTACGTACATCT	362
TIMP-3	529	ATACGGAAGCTTCCGAGAGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAG	578
ChIMP-3	363	ACACAGAAGCCTCAGAGAGTCTTTGTGGTGTGAAACTGGAGGTCAACAAA	412
TIMP-3	579	TACCAGTACCTGCTGACAGGTCGCGTCTATGATGGCAAGATGTACACGGG	628
ChIMP-3	413	TACCAGTATCTGATTACAGGCCGCGTGTACGAAGGGAAGGTTTACACTGG	462
TIMP-3	629	GCTGTGCAACTTCGTGGAGAGGTGGGACCAGCTCACCTCTCCCAGCGCA	678
ChIMP-3	463	CCTGTGCAATTGGTATGAGAAATGGGACCGACTGACTCTGTCCCAGCGTA	512
TIMP-3	679	AGGGGCTGAACTATCGGTATCACCTGGGTGTAACTGCAAGATCAAGTCC	728
ChIMP-3	513	AAGGACTGAATCATCGTTATCATCTGGGCTGTGGATGCAAGATTTCGGCCC	562
TIMP-3	729	TGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGAC	778
ChIMP-3	563	TGCTACTATTTGCCCTGCTTTGCCACCTCCAAGAATGAGTGCATTTCGGAC	612
TIMP-3	779	CGACATGCTCTCCAATTCGGTTACCCTGGCTACCAGTCCAAACACTACG	828
ChIMP-3	613	AGACATGCTCTCCAACTTCGGCCACTCAGGACACCAAGCGAAGCACTATG	662
TIMP-3	829	CCTGCATCCGGCAGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGGC	878
ChIMP-3	663	CCTGCATCCAGAGGGTGAAGGTTACTGCAGCTGGTATAGAGGATGGGGC	712

FIG. 7B

[illegible]

10/26

FIG. 8

TIMP-3 1 MTPWLGLIVLLGSWSLGDWGAEACTCSPSHPD AFCNSDIVIRAK 45
 . | : | : | : | | . | : . | : | | . | | | : | | | . | : | | | |
 TIMP-2 1 MGAAARTLRLALG LLLLATLL . RPADACSCSPVHPQQAFCNADVIRAK 48
 TIMP-3 46 VVGKKLVKEG PFGTLVYTIKQMKMYRGFTKMPHVQYIHT EASES 89
 . | : . | | . . | : : | . | | | : | | : | . | . : : . | . : | . .
 TIMP-2 49 AVSEKEVD SGNDIYGNPIKRIQYEIKQIKMFKGPEK . DIEFIYTAPSSA 96
 TIMP-3 90 LCGLKLEV . NKYQYLLTGRVY . DGKMYTGLCNFVERWDQLT LSQRKGLNY 137
 : | | : . | : | . | : | | : . | . | | | . . | | : | : . | | | . | : | : | | .
 TIMP-2 97 VCGVSLDVGGKKEYLIAGKAEGDGKM HITLCDFIVP WDTLSTTQKKSLNH 146
 TIMP-3 138 RYHLGCNCKIKSCY YLPCFVTSKNECLWTDMLS NFGYPGYQSKHYACIRQ 187
 | | : : | | : | | . . | : | | : . | : | | | | : : . . | . | . | : | | : .
 TIMP-2 147 RYQMGCECKITRC PMIPCYISSPDECLWMDWVTEK NINGHQAKFFACIKR 196
 TIMP-3 188 KGGYCSWYRGWAPPDKSIINATDP 211
 . : | | . | | | | | | . . : : . | |
 TIMP-2 197 SDGSCAWYRGAAPPKQEFLDIEDP 220

SUBSTITUTE SHEET (RULE 26)

11/26

FIG. 9A

TIMP-3 1 GGCGGCGGGCGCTCAGACGGCTTCTCCTCCTCCTTGTCTCTCCAAGCT 50
 |||||
 TIMP-2 1GGGGCCGCCGAGAGCCGCGCGCCGCTCGCCCCGCCGCCCCCACC 45
 TIMP-3 51 CCTGTCTCTTCGCCGGGAGCCCGCCCGCCGAGTCTGCGCCAGCGCCGAG 100
 |||||
 TIMP-2 46 CCGCCGCCCCGCCGGCGAATTGCGCCCCGCGCCCTCCCCTCGCGCCCCC 95
 TIMP-3 101 GCAGCCTCGCTGCGCCCCATCCCGTCCCGCCGGGCACTCGGAGGGCAGCG 150
 |||||
 TIMP-2 96 GAGACAAAGAGGAGAGAAAGTTTGC GCGGCCGAGCGGGCAGGTGAGGAGG 145
 TIMP-3 151 CGCCGGAGGCCAAGGTTGCCCGCACGGCCCGGGCGGCGAGCGAGCTCGG 200
 |||||
 TIMP-2 146 GTGAGCCGCGCGGAGGGGCCCGCCTCGGCCCGGCTCAGCCCCCGCCCCG 195
 TIMP-3 201 GCTGCAGCAGCCCCGCCG.GCGGCGCGCACGGCAACTTTGGAGAGG.... 245
 |||||
 TIMP-2 196 GCCCCCAGCCCGCCGCGGAGCAGCGCCCGGACCCCCCAGCGGCGGCCC 245
 TIMP-3 246CGAGCAGCAGCCCCGGCAGCGGCGGCGAGCAGCGGCAATGACCCCTT 291
 |||||
 TIMP-2 246 CGCCCGCCAGCCCCCGGCCCGCCATGGGCGCCGCGGCCCGCACCCCTGC 295
 TIMP-3 292 GGCTCGGGCTCATCGTGCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGC 341
 |||||
 TIMP-2 296 GGCTGGCGCTCGGCCTCCTGCTG.....CTGGCGACGCTGCTTCGCCCCG 339
 TIMP-3 342 GCCGAGGCGTGACATGCTCGCCAGCCACCCCCAGGACGCCTTCTGCAA 391
 |||||
 TIMP-2 340 GCCGACGCCTGCAGCTGCTCCCCGGTGACCCGCAACAGGCGTTTGTCAA 389
 TIMP-3 392 CTCCGACATCGTGATCCGGGCCAAGGTGGTGGGGAAGAAGCTGGTAAAGG 441
 |||||
 TIMP-2 390 TGCAGATGTAGTGATCAGGGCCAAAGCGGTGAGTGAAGAAGTGGACT 439
 TIMP-3 442 AGGG.....GCCCTTCGGCACGCTGGTCTACACCATC 473
 |||||
 TIMP-2 440 CTGGAACGACATTTATGGCAACCCTATCAAGAGGATCCAGTATGAGATC 489
 TIMP-3 474 AAGCAGATGAAGATGTACCGAGGCTTACCAAGATGCCCCATGTGCAGTA 523
 |||||
 TIMP-2 490 AAGCAGATAAAGATGTTCAAAGGGCCTGAGAAG.....GATATAGAGTT 533
 TIMP-3 524 CATCCATACGGAAGCTTCCGAGAGTCTCTGTGGCCTTAAGCTGGAGGT.. 571
 |||||
 TIMP-2 534 TATCTACACGGCCCCCTCCTCGGCAGTGTTGGGGTCTCGCTGGACGTTG 583

FIG. 9B

TIMP-3	572	.CAACAAGTACCAGTACCTGCTGACAGGTCGCGTCTATG...ATGGCAAG	617
TIMP-2	584	GAGGAAAGAAGGAATATCTCATTGCAGGAAAGGCCGAGGGGGACGGCAAG	633
TIMP-3	618	ATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACCAGCTCACCT	667
TIMP-2	634	ATGCACATCACCTCTGTGACTTCATCGTGCCCTGGGACACCTGAGCAC	683
TIMP-3	668	CTCCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTGTAACTGCA	717
TIMP-2	684	CACCCAGAAGAAGAGCCTGAACCACAGGTACCAGATGGGCTGCGAGTGCA	733
TIMP-3	718	AGATCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAG	767
TIMP-2	734	AGATCACGCGCTGCCCCATGATCCCGTGCTACATCTCCTCCCCGGACGAG	783
TIMP-3	768	TGTCTCTGGACCGACATGCTCTCCAATTTCCGTTACCCTGGCTACCAGTC	817
TIMP-2	784	TGCCTCTGGATGGACTGGGTACAGAGAAGAACATCAACGGGCACCAGGC	833
TIMP-3	818	CAAACACTACGCCCTGCATCCGGCAGAAGGGCGGCTACTGCAGCTGGTACC	867
TIMP-2	834	CAAGTTCTTCGCCCTGCATCAAGAGAAGTGACGGCTCCTGTGCGTGGTACC	883
TIMP-3	868	GAGGATGGGCCCCCCCCGGATAAAAGCATCATCAATGCCACAGACCCCTGA	917
TIMP-2	884	GCGGCGGGCGCCCCCAAGCAGGAGTTTCTCGACATCGAGGACCCATAA	933
TIMP-3	918	GCGCCAGACCCTGCCCCACCTCACTTCCCTCCCTTCCCGCTGAGCTTCCC	967
TIMP-2	934	GCAGGCCTCCAACGCCCTGTGGCCAACTGCAAAAAAAGCCTCCAAGGGT	983
TIMP-3	968	TTGGACACTAACTCTTCCCAGATGATGACAATGAAATTAGTGCCTGTTTT	1017
TIMP-2	984	TTGACTGGTCCAGCTCTGACATCCCTTCCTGGAAA.....CAGCATGA	1027
TIMP-3	1018	CTTGCAAATTTAGCACTTGGAAACATTTAAAGAAAGGTCTATGCTGTCATA	1067
TIMP-2	1028	ATAAAACACTCATCCCATGGGTCCAAATTAATATG.....	1062

TIMP-3	208	CAGCCCCGCGGCGGCGCGCACGGCAACTTTGGAGAGGCGAGCAGCAGCC	257
TIMP-2	225	CGGACCCCCCAGCGGCGGCCCGCC CGCCAGCCCCC	261
TIMP-3	258	CCGGCAGCGGCGGCGAGCAGCGGCAATGACCCCTTGGCTCGGGCTCATCGT	307
TIMP-2	262	CGGCCCGCCATGGGCGCCGCGGCCCGCACCTGCGGCTGGCGCTCGGCCT	311
TIMP-3	308	GCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGCGCCGAGGCGTGCACAT	357
TIMP-2	312	CCT GCTGCTGGCGACGCTGCTTCGCCCCG.GCCGACGCCTGCAGCT	355
TIMP-3	358	GCTCGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCGACATCGTGATC	407
TIMP-2	356	GCTCCCGGTGCACCCGCAACAGGCGTTTTTGCAATGCAGATGTAGTGATC	405
TIMP-3	408	CGGGCCAAGGTGGTGGGGAAGAAG CTGGTAA A	439
TIMP-2	406	AGGGCCAAAGCGGTCAGTGAGAAGGAAGTGGACTCTGGAAACGACATTTA	455
TIMP-3	440	GGAGGGGGCCCTTCGGCAGCTGGTCTACACCATCAAGCAGATGAAGATGT	489
TIMP-2	456	TGGCAACCCTATCAAGAGGATCCAGTATGAGATCAAGCAGATAAAGATGT	505
TIMP-3	490	ACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCT	539
TIMP-2	506	TCAAAGGGCCTGAGAAG GATATAGAGTTTATCTACACGGCCCCC	549
TIMP-3	540	TCCGAGAGTCTCTGTGGCCTTAAGCTGGAGGT . . CAACAAGTACCAGTA	586
TIMP-2	550	TCCTCGGCAGTGTGTGGGGTCTCGCTGGACGTTGGAGGAAAGAAGGAATA	599
TIMP-3	587	CCTGCTGACAGGTTCGCTCTA . . TGATGGCAAGATGTACACGGGGCTGT	633
TIMP-2	600	TCTCATTGCAGGAAAGGCCGAGGGGGACGGCAAGATGCACATCACCTCT	649
TIMP-3	634	GCAACTTCGTGGAGAGGTGGGACCAGCTCACCTCTCCCAGCGCAAGGGG	683
TIMP-2	650	GTGACTTCATCGTGCCCTGGGACACCCTGAGCACCACCCAGAAGAAGAGC	699
TIMP-3	684	CTGAACTATCGGTATCACCTGGGTTGTAAC TGCAAGATCAAGTCCTGCTA	733
TIMP-2	700	CTGAACCACAGGTACCAGATGGGCTGCGAGTGCAAGATCACGCGCTGCCC	749

14/26

FIG. 10B

TIMP-3	734	CTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCGACA	783
TIMP-2	750	CATGATCCCGTGCTACATCTCCTCCCCGGACGAGTGCCTCTGGATGGACT	799
TIMP-3	784	TGCTCTCCAATTTTCGGTTACCCTGGCTACCAGTCCAAACACTACGCCTGC	833
TIMP-2	800	GGGTCACAGAGAAGAACATCAACGGGCACCAGGCCAAGTTCTTCGCCTGC	849
TIMP-3	834	ATCCGGCAGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGGCCCCCCC	883
TIMP-2	850	ATCAAGAGAAGTGACGGCTCCTGTGCGTGGTACCGCGGCGGGCGCCCCC	899

SUBSTITUTE SHEET (RULE 26)

15/26

FIG. 11

TIMP-3 1 MAPFEPLASGILLLLWLIAPSR...ACTCVPPHPQTAFCONS DLVIRAKFV 47
 |.: .| |::| .: .: |||| |.|||.|||||:|||||. |
 TIMP-1 1 MTPWLGL...IVLLGSWSLGDWGAEACTCSPSH PQDAFCNS DIVIRAKVV 47
 TIMP-3 48 GTPEVNQTTL.YQRYEIKMTKMYKGFQALGDAADIRFVYTPAMESVCGYF 96
 |.. |.:.: |.|| ||::|| : :.:.:|. | |::||.
 TIMP-1 48 GKKLVKEGPFGLVYTIKQMKMYRGFTKM...PHVQYIHT EASESLCGL. 93
 TIMP-3 97 HRSHNRSEEFLLIAGKLQDGLLHITTC SFVAPWNSLSLAQRRGFTKTYTVG 146
 : . . . :|:|:|: || :.. |.|||. |: |. |. |:|:| : | :|
 TIMP-1 94 .KLEVNKYQYLLTGRVYDGKMYTGLCNFVERWDQLT LSQRKGLNYRYHLG 142
 TIMP-3 147 CEECTVFPCL SIPCKLQSGTHCLWTDQLLQSEKGFQSRHLACLPREPGL 196
 | :|: .|. :|| : | ..||| | . : .|:|:|. |.:...|. |
 TIMP-1 143 C.NCKIKSCYILPCFVTSKNECLWTDMLS NFGYPGYQSKHYACIRQKGGY 191
 TIMP-3 197 CTWQSLRSQIA..... 207
 |. | . :. .
 TIMP-1 192 CSWYRGWAPPDKSIINATDP 211

SUBSTITUTE SHEET (RULE 26)

16/26

FIG. 12A

TIMP-3	201	GCTGCAGCAGCCCCGCCGGCGGCGCGCACGGCAACTTTGGAGAGGCGAGC	250
TIMP-1	1AGGGGCCTTAGCGTGCCGCATCGCCGAGATC	31
TIMP-3	251	AGCAGCCCCGGCAGCGGCGGCGAGCAGCGGCAATGACCCCTTGGCTCGGGC	300
TIMP-1	32	CAGCGCCAGAGAGACACCAGAGAACCCACCATGGCCCCCTTTGAGCCCC	81
TIMP-3	301	TCATCGTGCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGCGCCGAGGCG	350
TIMP-1	82	TGGCTTCTGGCATCCTGTTGTTGCTGTGGCTGATAGCCCCCAGCAGGGCC	131
TIMP-3	351	TGCACATGCTCGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCGACAT	400
TIMP-1	132	TGCACCTGTGTCCACCCACCCACAGACGGCCTTCTGCAATTCCGACCT	181
TIMP-3	401	CGTGATCCGGGCCAAGGTGGTGGGGAAGAAGCTGGTAAAGGAGGGGCCCT	450
TIMP-1	182	CGTCATCAGGGCCAAGTTCGTGGGGACACCAGAAGTCAACCAGACCACCT	231
TIMP-3	451	TCGGCACGC.....TGGTCTACACCATCAAGCAGATGAAGATGTACCGA	494
TIMP-1	232	TATACCAGCGTTATGAGATCAAGATGACCAAGATGTATAAAGGGTTCCAA	281
TIMP-3	495	GGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCTTCCGA	544
TIMP-1	282	GCCTTAGGGGATGCCGCTGACATCCGGTTCGTCTACACCCCGCCATGGA	331
TIMP-3	545	GAGTCTCTGTGG.....CCTTAAGCTGGAGGTCAACAAGTACCAGTACC	588
TIMP-1	332	GAGTGTCTGCGGATACTTCCACAGGTCCCACAACCGCAGCGAGGAGTTTC	381
TIMP-3	589	TGCTGACAGGTGCGGTCTATGATGGCAAGATGTACACGGGGCTGTGCAAC	638
TIMP-1	382	TCATTGCTGGAAAAGTGCAGGATGGACTCTTGACATCACTACCTGCAGT	431
TIMP-3	639	TTCGTGGAGAGGTGGGACCAGCTCACCTCTCCCAGCGCAAGGGGCTGAA	688
TIMP-1	432	TTCGTGGCTCCCTGGAACAGCCTGAGCTTAGCTCAGCGCCGGGGCTTCAC	481
TIMP-3	689	CTATCGGTATCACCTGGGTTGT...AACTGCAAGATCAAGTCCTGCTACT	735
TIMP-1	482	CAAGACCTACACTGTTGGCTGTGAGGAATGCACAGTGTTTCCCTGTTTAT	531
TIMP-3	736	ACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCGACATG	785
TIMP-1	532	CCATCCCCTGCAAACTGCAGAGTGGCACTCATTGCTTGTGGACGGACCAG	581

17/26

FIG. 12 B

TIMP-3	786	CTCTCCAATTTTCGGTTACCCCTGGCTACCAGTCCAAACACTACGCCTGCAT	835
TIMP-1	582	CTCCTCCAAGGCTCTGAAAAGGGCTTCCAGTCCCGTCACCTTGCCTGCCT	631
TIMP-3	836	CCGGCAGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCCCCGG	885
TIMP-1	632	GCCTCGGGAGCCAGGGCTGTGCACCTGGCAGTCCCTGCGGTCCCAGATAG	681
TIMP-3	886	ATAAAAGCATCATCAATGCCACAGACCCCTGAGCGCCAGACCCTGCCCCA	935
TIMP-1	682	CCTGAATCCTGCCCGGAGTGAA.....CTGAAGCCTGCACAGTGTCCAC	726
TIMP-3	936	CCTCACTTCCCTCCCTTCCCGCTGAGCTTCCCTTGGACACTAACTCTTCC	985
TIMP-1	727	CCTGTTCCCACTCCCATCTTTCTTCCGGACAATGAAATAAAGAGTTACCA	776
TIMP-3	986	CAGATGATGACAATGAAATTAGTGCCTGTTTTCTTGCAAATTTAGCACTT	1035
TIMP-1	777	CCCAGC.....	782

FIG. 13

```

TIMP-3  347  GCGGTGCACATGCTCGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCG 396
          ||| ||||| ||  ||  ||||| |||  ||||| ||||| |||||
TIMP-1  128  GGCCTGCACCTGTGTCCACCCCACCCACAGACGGCCTTCTGCAATTCCG 177
          ||| ||||| |||  ||||| ||||| ||||| ||||| |||||
TIMP-3  397  ACATCGTGATCCGGGCCAAGGTGGTGGGGAAGAAGCTGGTAAAGGAGGGG 446
          ||  ||||| |||  ||||| ||||| ||||| ||||| |||||
TIMP-1  178  ACCTCGTCATCAGGGCCAAGTTCGTGGGGACACCAGAAGTCAACCAGACC 227
          ||  ||||| |||  ||||| ||||| ||||| ||||| |||||
TIMP-3  447  CCCTTCGGCACGCTGGTCTACACCATCAAGCAGATGAAGATGTACCGAGG 496
          ||||| ||  ||  ||  ||||| ||  ||  ||||| |||||
TIMP-1  228  ACCTTATAC...CAGCGTTATGAGATCAAGATGACCAAGATGTATAAAGG 274
          |||||
TIMP-3  497  CTTC 500
          |||
TIMP-1  275  GTTC 278

```

19/26




FIG. 14A

SUBSTITUTE SHEET (RULE 26)

20/26




FIG. 14B

SUBSTITUTE SHEET (RULE 26)




FIG. 15

22/26

FIG. 16A

TIMP3clone7	GGCGGCGGGCGCTCAGACGGCTTCTCCTCCTCCTTGCTCCTCCAAGCTCCTGCTCCTT	60
TIMP3clone2	
TIMP3HCM-3	
TIMP3PCR29	
TIMP3clone7	CGCCGGGAGCCCGCCCGCGAGTCCTGCGCCAGCGCCGAGGCAGCCTCGCTGCGCCCCAT	120
TIMP3clone2	
TIMP3HCM-3	
TIMP3PCR29	
TIMP3clone7	CCCGTCCCGCCGGGCACTCGGAGGGCAGCGCGCCGAGGCCAAGGTTGCCCCGCACGGCC	180
TIMP3clone2	
TIMP3HCM-3	
TIMP3PCR29	
TIMP3clone7	CGGCGGGCGAGCGAGCTCGGGCTGCAGCAGCCCCGCGGGCGCGCACGGCAACTTTGG	240
TIMP3clone2	
TIMP3HCM-3	
TIMP3PCR29	
TIMP3clone7	AGAGGCGAGCAGCAGCCCCGGCAGCGGGCGGAGCAGCGGCAATGACCCCTTGGCTCGGGC	300
TIMP3clone2	
TIMP3HCM-3	
TIMP3PCR29	
	MetThrProTrpLeuGlyL	-16
TIMP3clone7	TCATCGTGCTCCTGGGCGAGCTGGGCGACTGGGGCGCCGAGGCGTGCACATGCT	360
TIMP3clone2CAGGAGCCTGGGGGACTGGGGCGCCGAGGCGTGCACATGCT	40
	Arg	
TIMP3HCM-3	
TIMP3PCR29	
TIMP3clone7	erProSerHisProGlnAspAlaPheCysAsnSerAspIleValIleArgAlaLysValV	25
	CGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCGACATCGTGATCCGGGCCAAGGTGG	420
TIMP3clone2	CGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCGACATCGTGATCCGGGCCAAGGTGG	100
TIMP3HCM-3	
TIMP3PCR29	

SUBSTITUTE SHEET (RULE 26)

23/26

FIG. 16B

	alGlyLysLysLeuValLysGluGlyProPheGlyThrLeuValTyrThrIleLysGlnM	45
TIMP3clone7	TGGGGAAGAAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGGTCTACACCATCAAGCAGA	480
TIMP3clone2	TGGGGAAGAAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGGTCTACACCATCAAGCAGA	160
TIMP3HCM-3	..GGGAAGAAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGGTCTACACCATCAAGCAGA	58
TIMP3PCR29	
	etLysMetTyrArgGlyPheThrLysMetProHisValGlnTyrIleHisThrGluAlaS	65
TIMP3clone7	TGAAGATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCTT	540
TIMP3clone2	TGAAGATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCACACGGAAGCTT	220
TIMP3HCM-3	TGAAGATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCTT	118
TIMP3PCR29	
	erGluSerLeuCysGlyLeuLysLeuGluValAsnLysTyrGlnTyrLeuLeuThrGlyA	85
TIMP3clone7	CCGAGAGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAGGTC	600
TIMP3clone2	CCGAGAGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAGGTC	280
TIMP3HCM-3	CCGAGAGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAGGTC	178
TIMP3PCR29	
	rgValTyrAspGlyLysMetTyrThrGlyLeuCysAsnPheValGluArgTrpAspGlnL	105
TIMP3clone7	GCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACCAGC	660
TIMP3clone2	GCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACCAGC	340
TIMP3HCM-3	GCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACCAGC	238
TIMP3PCR29	
	euThrLeuSerGlnArgLysGlyLeuAsnTyrArgTyrHisLeuGlyCysAsnCysLysI	125
TIMP3clone7	TCACCCTCTCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTGTAACTGCAAGA	720
TIMP3clone2	TCACCCTCTCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTGTAACTGCAAGA	400
TIMP3HCM-3	TCACCCTCTCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTGTAACTGCAAGA	298
TIMP3PCR29	

24/26


FIG. 16C

	leLysSerCysTyrTyrLeuProCysPheValThrSerLysAsnGluCysLeuTrpThrA	145
TIMP3clone7	TCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCG	780
TIMP3clone2	TCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCG	460
TIMP3HCM-3	TCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCG	358
TIMP3PCR29CTCTGGACCG	10
	spMetLeuSerAsnPheGlyTyrProGlyTyrGlnSerLysHisTyrAlaCysIleArgG	165
TIMP3clone7	ACATGCTCTCCAATTTCGGTTACCCTGGCTACCAGTCCAAACACTACGCCTGCATCCGGC	840
TIMP3clone2	ACATGCTCTCCAATTTCGGTTACCCTGGCTACCAGTCCAAACACTACGCCTGCATCCGGC	520
TIMP3HCM-3	ACATGCTCTCCAATTTCGGTTACCCTGGCTACCAGTCCAAACACTACGCCTGCATCCGGC	418
TIMP3PCR29	ACATGCTCTCCAATTTCGGTTACCCTGGCTACCAGTCCAAACACTACACATGCTCGCCA	70
	Thr SerProS	
	lnLysGlyGlyTyrCysSerTrpTyrArgGlyTrpAlaProProAspLysSerIleIleA	185
TIMP3clone7	AGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCGGATAAAAAGCATCATCA	900
TIMP3clone2	AGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCGGATAAAAAGCATCATCA	580
TIMP3HCM-3	AGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCGGATAAAAAGCATCATCA	478
TIMP3PCR29	GCCACCCCGCACGCGCTCCCG.....	130
	erHisProArgThrArg	
	snAlaThrAspProEnd	205
TIMP3clone7	ATGCCACAGACCCCTGAGCGCCAGACCCTGCCCCACCTCACTTCCCTCCCTTCCCGCTGA	960
TIMP3clone2	ATGCCACAGACCCCTGAGCGCCAGACCCTGCCCCACCTCACTTCCCTCCCTTCCCGCTGA	640
TIMP3HCM-3	ATGCCACAGACCCCTGAGCGCCAGACCCTGCCCCACCTCACTTCCCTCCCTTCCCGCTGA	538
TIMP3PCR29	190
	GCTTCCCTTGGACACTAACTCTTCCCAGATGATGACAATGAAATTAGTGCCTGTTTTCTT	1020
TIMP3clone7		
TIMP3clone2	GCTTCCCTTGGACACTAACTCTTCCCAGATGATGACAATGAAATTAGTGCCTGTTTTCTT	700
TIMP3HCM-3	GCTTCCCTTGGACACTAACTCTTCCCAGATGATGACAATGAAATTAGTGCCTGTTTTCTT	598
TIMP3PCR29	250

FIG. 16D

SUBSTITUTE SHEET (RULE 26)

FIG. 17



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/11241

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/15 C07K14/81 C12N1/21 C12N5/10 A61K48/00
A61K38/57 A61K38/43 A61K38/17 A61K38/48 C07K16/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FASEB JOURNAL, vol.7, no.3, 19 February 1993, BETHESDA, MD US page A371 N. KISHNANI ET AL 'Metalloproteinase inhibitors in the extracellular matrix of cultured human cells' abstract 2148 ---	1-74
Y	JOURNAL OF BIOLOGICAL CHEMISTRY., vol.267, no.24, 25 August 1992, BALTIMORE US pages 17321 - 17326 N. PAVLOFF ET AL 'A new inhibitor of metalloproteinases from chicken: ChIMP-3' cited in the application see the whole document --- -/--	1-74

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 January 1995

Date of mailing of the international search report

- 7. 02. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 94/11241

C/(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol.261, no.6, 25 February 1986, BALTIMORE, MD US pages 2814 - 2818 G. HERRON ET AL 'Secretion of metalloproteinases by stimulated capillary endothelial cells' see abstract see page 2816, left column, last paragraph - page 2817, left column see page 2818, left column, paragraph 5 ---	1-74
A	JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol.265, no.23, 15 August 1990, BALTIMORE, MD US pages 13933 - 13938 W. STETLER-STEVENSON ET AL 'Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues' ---	
P,X	GENE., vol.141, June 1994, AMSTERDAM NL pages 293 - 297 S. SILBIGER ET AL 'Cloning of cDNAs encoding human TIMP-3, a novel member of the tissue inhibitor of metalloproteinase family' see the whole document ---	1-74
P,X	CANCER RESEARCH, vol.54, 15 April 1994 pages 2091 - 2094 J. URIA ET AL 'Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family' see the whole document ---	1-74
E	CHEMICAL ABSTRACTS, vol. 121, no. 17, 24 October 1994, Columbus, Ohio, US; abstract no. 197175, S. APTE ET AL 'Cloning of the cDNA encoding human tissue inhibitor of metalloproteinase-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22' see abstract ---	1-74
P,X	& GENOMICS, vol.19, no.1, 1994 pages 86 - 90 ---	1-74

	-/--	

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/US 94/11241

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	<p>JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol.269, no.12, 25 March 1994, BALTIMORE, MD US pages 9352 - 9360 K. LECO ET AL 'Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues' see the whole document -----</p>	1-74

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.